Synthesis and properties of resorcin[4]arene based quadrupoles and dimeric electrostatic capsules by Atkins, Joseph
 SYNTHESIS AND PROPERTIES OF RESORCIN[4]ARENE BASED 
QUADRUPOLES AND DIMERIC ELECTROSTATIC CAPSULES 
 
 
 
BY  
JOSEPH ATKINS 
 
 
 
B.S., University of Illinois at Urbana-Champaign, 2003 
 
AN ABSTRACT OF A DISSERTATION 
 
Submitted in partial fulfillment of the requirements for the degree 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Department of Chemistry 
 
College of Arts and Sciences 
 
 
KANSAS STATE UNIVERISTY 
Manhattan, Kansas 
2009 
 
 
 Abstract 
 
In the present study, the rescorcin[4]arenes decorated with an alternating 
arrangement of pyridinium and sulfonate moieties were synthesized to establish 
a molecular quadrupole.  These rescorcin[4]arenes are capable of undergoing 
conformational changes from a ‘collapsed’ to ‘open’ state.  The stability of the two 
state are controlled by the polarity of the solvent environment.  The electrostatic 
interactions between pyridinium and sulfonates enforced a ‘quadrupolar collapse’ 
in solvents such as chloroform.  While these interactions are disrupted in 
dimethylsulfoxide. 
 A major synthetic challenge was functionalizing the resorcin[4]arene in a 
positive/negative/positve/negative pattern was successfully addressed.  
Comparison to dipolar resorcin[4]arene were undertaken to establish a 
quantitative measurement of the quadrupolar forces and to address the question 
of cooperatively provided addition attraction beyond two dipoles. 
 A,C-functionalized-bis sulfonate resorcin[4]arenes and A,C function bis-
pyridinium resocin[4]arenes were synthesized independently.  Combining these 
dicationic and dianionic moieties provided an interdigitating dimeric unit with 
overall quadrupolar charge distribution. 
 Disruption of the quadrupolar salt bridges in CDCl3 was accomplished 
through the addition of DMSO or through dilution.  ΔGo, ΔHo, and ΔSo have been 
determined for the dimer formation.  Addition of pyridinium salts led to a 
disruption of the dimeric capsule.   
Host-guest binding studies established attractive binding to CS2. Larger 
guests such as toluene, diiodobenzene, dicynanobenzene could not be 
encapsulated.  
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1 
Chapter 1 Introduction 
.1.1 What is a Cavitand? 
 
In 1982 Cram proposed the term ‘cavitand’ as a molecule with an inner 
cavity large enough to accommodate guest molecules or ions.1   Spherands (1)2 
which are useful alkali metal ion complexion, cycloteveratrylene (2)3, which has a 
saucer shape which can be stitched together to generate a capsule-like molecule 
(3)3.  Cavitands (5-7) generated from resorcinol-acetaldehyde condensations 
which can be decorated with various functional groups.1  Cram, Rebek, and 
Diederich have had great contributions to the diazanapthalene bridged 
cavitands(7) which exhibit a conformational change between vase C4v to kite C2v 
conformation.  The diazanapthalene bridged (7) cavitand undergoes a 
conformation change from a vase to kite conformation which is the upper arms 
are held together based on an external stimulus.  The arms of the aromatic walls 
are distant relative to each other in the kite while the arms are held together by 
hydrogen bonding in the vase conformation.   
2 
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Figure 1.1 Different types of cavitands. 
3 
1.2 What are cavitand’s uses? 
 
Cavitands contain cavities, which are capable to accommodate guest 
molecules or ions.  Rebek introduced self-folding capsules (8) which can 
accommodate adamatanes, lactams, and cyclohexanes in amide substituted 
cavitands4 (Figure 1.2). These supramolecular structures can reversibly change 
from a vase C4v to kite C2v conformation.  Eight intramolecular hydrogen bonds 
stitch together the seams of the cavitand’s upper arms holding the aromatic walls 
together for a stable vase-like structure.  These intramolecular hydrogen bonds 
can be ruptured to release solvents molecules and pre-bind guest molecules 
while reforming the intramolecular hydrogen bonds to generate a stable host 
guest complex. 
 
Figure 1.2 Rebek's reversible self-folding Cavitand. 
 
Rebek and co-workers5 generate molecular capsules through a hydrogen 
bonding network with two cavitands (Figure 1.3).   These complexes are 
generated with guest molecules such as quniclinidine, with recystillization from 
methanol yielding dimeric capsules.  These studies demonstrate solvents such 
as methanol, wet acetonitrile, and water is essential to promote formation of 
these networks.   
 
4 
 
Figure 1.3 shows Cram's solvent stabilized capsule. 
Cavitands decorated with pyrazine dicarboximide, which are hydrogen 
bond donors, and acceptors (9), can form 1:1 complexes, which accommodate 
guest molecules and amplify chemicals reactions such as ring/chain 
isomerization reaction.  The use of a  
 
Figure 1.4  Dimeric Capsule through Hydrogen Bonding 
cavitand based molecular capsule can shift the equilibrium to the oxazine from 
the Schiff’s base.  As shown in the diagram below the use of the 1:1 capsule 
creates an environment more conducive for the isomerization of the Schiff’s base  
to oxazine.  As shown in the scheme below amount of 10 and 12 is greatly 
diminished with the use of a molecular capsule held together by hydrogen bonds. 
 
 
5 
 
 
 
 
 
1.3 Conformational Change 
1.3a What is conformational change? 
 
Conformational change is when a molecule changes its morphology due 
to functional moieties changing their relative orientation through space.  For 
example this biopolymer undergoes a conformational change from a random coil 
to a helical type conformation6.  The helical conformation is held together by 
Figure 1.5 shows capsule promoted ring isomerization 
6 
aromatic п-stacking units (15).  Polar solvents such as acetonitrile drive these 
oligomers to fold into an ordered state while chloroform pushes the equilibrium to 
the random coil. 
 
 
Figure 1.6 Jeffery Moore's conformational change from random coil to ordered helices. 
 
The most significant conformational change was established with Cram’s 
quinoxaline bridged cavitands.1 External stimuli such as temperature and pH 
exerted a change from a vase C4v to kite C2v conformation.  
Others such as Diederich et al7 have used  chloroform-d(CDCl3) or 
methylene chloride (CD2Cl2) with trifluoro acetic acid (TFA) led to the kite 
conformation.  Potassium carbonate was employed to raise the pH thus changing 
the conformation from a kite vase.  
 
Figure 1.7 Cram’s quinoxaline bridged cavitand which undergo transformation from vase to kite. 
 
7 
 
 
Conformational dynamics in enzymes is important to understand the 
allosteric regulation for binding of substrates.  This conformational change that 
occurs within the enzyme is due to an allosteric activator, which is transmitted to 
the active site. 8 Similar to Cram’s system1 Badjic  
 
Figure 1.7 Badjic Cavitand with flaps capable of interconverting by enantiomers. 
 
designed a cavitand (15) with flaps capable of interconverting between two 
enantiomers.  Their results demonstrated chloroform with triflouroacetic acid 
slowed down the interconversion between the two enantiomers.  They found a 
ΔGo = 13.3 kcal/mol for 0 equivalents of TFA and ΔGo = 15 kcal/mol for 17 
equivalents of TFA.  As a result the allosteric effect is regulated by acid.  
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1.4 Electrostatics 
1.4a How are electrostatics forces implemented in supramolecular 
systems? 
Ion pairing are attractive forces present in many biological systems.  For 
example proteins contain ammonium and carboxylate salts such as lysine and 
glutamic acid.  These electrostatic forces are termed as Coulomb attractions, 
which are defined as: 
 
 
 
 
 
 
 
 
where q is the force on the charge, r is the separation of the charges, ε is the 
permittivity of the vacuum and E is the electric field in the space around the 
charge.9 The electrostatic forces are great diminished in solvents with high 
dielectric constants.  As a result solvents with low dielectric constants are 
employed to observe electrostatic forces in ionic pairs. For our purposes the 
paper involves the study of electrostatic forces within supramolecular host 
structures therefore solvents with low dielectric constants are employed. 
 Hans-Jorg Schneider studied association constants of 10 ion pairs in 
water by NMR titrations.10 All ten ion pairs were around 16 kJmol-1 meaning each 
ion pair is 8 kJ/mol-1.  The difference between the strongest and weakest 
complexes in ΔGo values is -12.6 and 16.3 kJmol-1 ,  which is surprisingly small. A 
linear correlation was found between the ΔG and number of bonds, which yields 
a ΔΔG of 0.5 kJmol-1  
E = 
q1 q2 
4 πεεo r2  
Equation 1.1 calculation for electrostatic forces. 
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Figure 1.8 shows 10 ion pairs studied by Schneider et al. 
 
.1.5 Supramolecular Electrostatic Assemblies 
Many are interested in forming assemblies based on electrostatic forces.  This 
section will focus on the current uses of cavitand-based assemblies of molecular 
capsules.  Reinhoudt has done fabulous work with uses electrostatics for 
generating molecular capsules.   Reinhoudt and coworkers11 employ two 
pyridium half capsules with held together by sulfonates through electrostatic self-
assembly. 
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Figure 1.9 tetra(kis)-methylpyridinium half capsule and doubly charged anions that are complexed. 
 
Tetra(kis)-methylpyridium half capsule are complexed with a doubly 
charged anions such as sulfonate and carboxylates to generate a capsule based 
on salt bridges.  An electrostatic self-assembly generates H2A4 and H2A3 dimers 
where ‘H’ is the half bowl and ‘A’ is the anionic species.  NMR dilution studies 
were performed in methanol d-4 and H2A3 is 3.25 x1012 M-4 and H2A4 is 3.45 x 
1015 H2A4.  These capsules possess cavities capable of accommodating methyl 
and ethyl esters of 4-aminio benzoic acid, 4-iodophenol and 4-iodoaniline.     
Reinhoudt and coworkers12 decorate a cavitand with pyridiums and complex it  
with a sulfonate functionalized calixarene.  By NMR and UV dilution studies Ka 
Values of 2•106 M-1 were determined in methanol and water-methanol mixtures.   
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These molecular capsules inner cavity are smaller than Rebek’s13 systems due 
there ability to encapsulate molecules such as methanol, ethanol, propanol, and 
n-amyl alcohol. 
 
Figure 1.10 shows the sulfonate caliaxarene and tetrapyridinium cavitand. 
 
Reinhoudt also developed a water-soluble electrostatic assembly between 
a tetra-carboxylate and tetra-amidinium capsule.  There studies proved two 
oppositely charged calixarenes could accommodate small guest molecule such 
as N-methyl quinuclidinium in water.  They calculated ΔH = -3.3 kcal/mol-1 due to 
the favorable interaction between the two oppositely charged calixarenes and 
TΔS= 2.9 kcal/mol-1.  This evidence supports supramolecular complexes can 
potentially serve as drug delivery tools.14 
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Figure 1.11 shows the tetracaboxylate and tetramidinium capsule. 
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Chapter 2 Early Efforts Toward Conformational 
Change with 1,2,3 Triazole based 
Resorcin[4]arenes 
2.1,1 Introduction 
The use of benzyl substituted resorcin[4]arenes were synthesized to 
provide flexible arms capable changing there orientation in space  generating an 
overall change in the morphology of the cavitand.  These arms are decorated 
with 1,2,3 triazoles which act as linkers to position aromatic groups on the upper 
rim of the cavitand.  The 1,2,3 triazoles were synthesized via a 1,3 dipolar 
addition.   The use of external stimuli such as acid and solvent environment is 
employed to promote a conformational change in the cavitand.  The use of 1H 
NMR and 2D NOESY is utilized to monitor the conformational change.   
2.1,2-1,2,3 triazole methylene cavitands for conformational 
control 
 
Initially, our focus was directed on conformational change with 
supramolecular host structures mediated by a pH control switching mechanism.  
We envisioned an ‘open state’ that is closed conformation mediated, for example, 
by the hydrophobic effect16.  By lowering the pH we envisioned the triazoles 
would be protonated and through charge repulsion a conformational change 
would undergo.  The ‘open state’ is an open conformation capable of binding 
guest molecules as seen in Figure 2.1.   
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Scheme 2.1 pH mediated conformation of 1,2,3 triazole cavitand. 
 
 
2.1,3-Synthesis of 1,2,3 tetratriazole phenyl cavitand: 
 
The synthesis of the tetrabromo methylene cavitand 2-2 has been well 
established by Sherman17 (Figure 2.2).  The first step is the acid catalyzed 
condensation with hexanal and methyl resorcinol.  After drying under high-
vacuum the octanol 2-1 was suitable for bridging the seams with 
bromochloromethane in DMF.1 The bridged methyl cavitand 2-2 was brominated 
via an oxidative addition with NBS and diphenyl peroxide to give 2-317.  The 
benzyl bromides 2-3 were converted to azides with sodium azide in DMF to yield 
the tetra-azide cavitand 2-4.  1,3 dipolar cycloadditions of phenyl acetylene and 
the tetraazide cavitand to generate the tetra phenyl triazole cavitand 2-518. 2D-
NOESY19 was employed to confirm the presence of the 1,4 regioisomer from the 
cycloaddition by NOE signal between the triazole hydrogen and methylene 
connecting the triazole and the phenyl (Figure 2.3).  This was consistent with 
other acetylenes that were reacted with the tetra-azide cavitand such as pyridine 
alkynes. 
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Scheme 2.2 Tetrabromo methylene cavitand reaction scheme. 
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Figure 2.1 2-D NOESY of tetratriazole phenyl methylene cavitand 2-5. 
 
 
Our efforts were focused on the decorating cavitands with 1,2,3 triazoles 
via 1,3 dipolar addition with benzyl azides and terminal alkynes.  This research 
established a new synthetic method for decorating cavitands with aromatic 
motifs.   Ultimately, hydrophobic effects would yield an attractive state generating 
a closed conformation.  Unfortunately, the 1,2,3 trizoles cavitands were not 
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soluble in water.  Attempts were made to protonate the triazole with concentrated 
sulfuric acid to generate a tetra-protonated triazole cavitand. Attempts with a 
model compound using an excess of H2SO4 and CF3COOH were unsuccessful 
(scheme 2.4).  
 
Scheme 2.2.3 Model Compound for protonation of triazole. 
 
Several studies were performed to bind substrates such as toluene, benzene, 
and para-toluene sulfonic acid.  Unfortunately, no cross-peaks were detected 
between the substrate and cavitand.  From these studies we established our 
cavitands were not water soluble or capable of binding small aromatic guests.  
 
2.1,4-1,2,3 triazole quadrupole cavitand: 
 
Our efforts altered from “closed” to “open” confirmation to an “open” to 
“closed” conformation.  We envisioned the use of a quadrupolar orientation of 
charges on the upper rim of the cavitand would yield an attractive force to bring 
aromatic moieties together.  The 1,2,3 triazoles would act as linkers between the 
cavitand and aromatic moieties (Figure 2.4).  The methylene bridges provide 
flexibility for the charged species to orient themselves through space for a 
positve/negative/positve/negative pattern on the upper rim of the cavitand.   
20 
O O
OO
O O O
C5H11
C5H11C5H11 C5H11
H
HH
H
N N
N
N
N
N
N
N
N
N
N
N
HN
NH
S
O
O
O
S OO
O
 
 
Figure 2.4: 1,2,3 triazole quadrupole 
 
2.1,5-Synthesis of 1,2,3 triazole based Quadrupole 
 
The key challenge to the synthesis of a molecular quadrupole is the 
functionalization cationic and anionic functional moieties on the upper rim in an 
alternating pattern.  The established 1,3 dipolar addition was employed to 
generate molecular quadrupole. Key intermediates A,C-bis-pyridinium cavitands 
or A,C-bis-sulfonate cavitands became key synthetic targets in our endeavors  
(Figure 2.5). 
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Figure 2.5 Bis-A,C functionalized 1,2,3 triazole cavitand. 
 
2.1,6 Key Intermediate:bis-A,C pyridine, sulfonate 1,2,3 triazole 
 
Our approach to the partial A,C fuctionalization of the upper rim  of a 
cavitand is inherently statistical in nature as we missed 2-11 (Figure 2.6) and 
approximately two equivalents of pyridinium acetylene in a cycloaddition reaction.  
The reaction showed essentially no chemo- or regioselectivity.  This gave rise to 
a mixture of mono-, bis-, tris- and tetrafunctionalized cavitands (Figure 2.7).  
Furthermore, the bis-functionalized cavitand was formed as a 1:2 mixture of the 
A,B 2-13 and the desired A,C-cavitand 2-11.  The use different isolation 
techniques such as flash chromatography and reverse phase HPLC with different 
columns such as C18, C8 and cyano was utilized.  After surveying different 
isolation techniques, flash chromatography with chloroform/methanol mixtures 
yielded the isolation of the desired bis-A,C pyridine cavitand.  The isolation of the 
bis-A,C sulfonate cavitand was not successful  even after many attempts with 
hexane/ethyl acetate mixtures. 
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Scheme 2.4 Mixture of isomers generated from 1,3 dipolar addition 
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The most challenging separation is the bis-A,B functionalized cavitand from the 
desired bis-A,C cavitand.  These two isomers are similar in polarity and cause 
separation of these isomers a challenging task.  The A,B isomer is also 
statistically preferred over the A,C isomer due to by a factor of 2.  After isolating 
the desired compound 2-11 in low yield, the remaining azides were functionalized 
with phenyl-substituted sulfonates (Table 2.1). 
Isomer Yield (Isolated) 
Mono 2-11a 17.5 % 
A,B Bis 2-13 24.0% 
A,C Bis 2-11 5.0% 
Tris 2-11b 35.0% 
Tetra 2-11c 18.0% 
Table 2-1 Isolated Yields from 1,3 dipolar addtion for A,C bis intermediate. 
 
    The remaining two steps involve creating cationic and anionic changes in 
the molecule.  The pyridine is alkylated with methyl iodide to yield pyridinium 
iodide 2-15 (Figure 2.8).  Subsequently the anionic sulfonates are released by 
KOH in methanol and methylene chloride to yield an overall neutral compound 2-
16.  After several NMR tests in chloroform I was unable to detect any signals to 
observe an electrostatic effects.  Due to the poor solubility of in chloroform, which 
is a solvent conducive for tight ion pairing.  As a result, this synthetic method was 
abandoned.   
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Scheme 2.5 shows 1,3 dipolar addition with sulfonate alkyne and B,D-bis-azide, A,C-bis-
pyridine cavitand.shows  
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The focus was altered to extend the feet of the cavitand to increase the solubility 
of the cavitand in non-polar solvents. 
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Scheme 2.6 shows the alkylation of the pyridine and deprotection of the sulfonate from the 
cavitand. 
2.1,7-Conclusion 
 
The use of benzyl substituted resorcin[4]arenas was synthesized via a 1,3 
dipolar addition.  A quadrupolar arrangement of an alternating 
pyridinium/sulfonate/pyridinium/sulfonate was successfully addressed.  
Unfortunately, poor solubility of these resorcin[4]arenes in non-polar solvents 
such as chloroform is not a conducive environment for electrostatics.  Future 
efforts were focused to increase the solubility of the cavitand in non-polar solvent 
by extending the chain length of the feet of the resorcin[4]arene.   
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2.2 Experimental Section  
C-pentyl methyl calix[4]resorcinarene[2-1] 
 
HOOH OH
OHHO
HO OH HO
C5H11
C5H11C5H11 C5H11
H
HH
H
 
Compound 2- 1 
 
To a solution of 2 methyl-resorcinol (17.0 g, 136 mmol) and hexanal (13.7 g, 137 
mmol) in ethanol (136 mL) was added concentrated HCl (37.0 mL) at 0ºC under 
an inert atmosphere. A condenser was attached and the mixture heated to 70°C 
overnight. The reaction was allowed to cool to room temperature upon 
completion, then diluted with water. A white precipitate formed which was filtered 
and dried under high vacuum (80.0 g; 70%  Yield)of the title compound 2-1.15 1H 
NMR (400 MHz, DMSO-d6)   δ 0.85 (t, J=7.05 Hz, 12 H) 1.27 (s, 32 H) 1.94 (s, 
12 H) 2.16 - 2.27 (m, 5 H) 4.19 (s, J=9.71 Hz, 4 H) 7.25 (s, 4 H) 8.65 (s, 8 H);13C 
NMR (101 MHz, CDCl3)   δ 9.98, 13.9, 22.3, 27.6, 31.4, 33.0, 34.3, 111.6, 
121.0, 124.8, 148.9, 
 
 
 
26 
C-Pentyl tetramethyl resorcin[4]arene[2-2] 
OO O
OO
O O O
C5H11
C5H11C5H11 C5H11
H
HH
H
 
Compound 2- 2 
 
Dried methyl octanol cavitand 2-1 (12.6 g, 15.3 mmol), 
bromochloromethane(14.0 g, 108 mmol), and potassium carbonate (44.3 g 320 
mmol) in dimethylformamide (340 mL) was stirred under an inert atmosphere for 
3 days.  After 24 hours the (3.95 g 30.5 mmol 2.00 mL) was added to the solution 
and repeated on the following day.  The solvent was removed via distillation and 
the remaining residue was dissolved in dichloromethane.  The organic layer was 
washed with 2M HCl, water, and brine and then dried with magnesium sulfate, 
filtered and concentrated under vacuum.  The crude was purified by column 
chromatography 4:1 hexane:ethyl acetate to give (10.6 g 80% yield) of the title 
compound 2-2 1H NMR (400 MHz, CDCl3)   δ 0.91 (t, J=7.1 Hz, 12 H) 1.29 - 
1.48 (m, 26 H) 1.97 (s, 12 H) 2.12 - 2.27 (m, J=8.1 Hz, 8 H) 4.26 (d, J=7.0 Hz, 3 
H) 4.76 (t, J=8.10 Hz, 4 H) 5.88 (d, J=7.00 Hz, 4 H) 6.98 (s, 3 H) 13C NMR (101 
MHz, CDCl3)   δ 10.3, 14.10, 22.7, 27.7, 30.1, 32.07, 37.0, 98.5, 117.6, 123.6, 
137.9, 153.2 
 
 
 
 
27 
C-Pentyl tetrabenzyl bromidel resorcin[4]arene[2-3] 
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Compound 2- 3 
 
Tetramethyl bridged cavitand 2-2(3.00 g 3.30 mmol), N-bromosuccinimide (2.41 
g 13.6 mmol), and benzoyl peroxide (0.040 g, 0.170 mmol) in carbon 
tetrachloride was stirred at 70oC overnight.  The reaction was allowed to cool to 
room temperature and filtered.  The solvent was removed via rotatory evaporator 
and the crude material was purified via column chromatography (4:1 Hexane: 
Ethyl Acetate) to give (3.50 g 90% Yield) of the title compound 2-3 1H NMR (400 
MHz, CDCl3)   δ 0.910 (t, J=7.00 Hz, 12 H) 1.18 - 1.53 (m, 24 H) 2.21 (q, 8 H) 
4.42 (s, 8 H) 4.56 (d, J=6.80 Hz, 4 H) 4.78 (t, J=8.00 Hz, 3 H) 6.02 (d, J=6.40 Hz, 
4 H) 7.13 (s, 4 H) 13C NMR (101 MHz, CDCl3)   δ 14.1, 22.65, 22.9, 27.5, 30.0, 
32.0, 36.9, 99.2, 120.9, 124.5, 138.1, 153.5  
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C-Pentyl tetrabenzyl azide resorcin[4]arene[2-4] 
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Compound 2- 4 
 
2.20 g (2.32 mmol) of tetrabromo cavitand 2-3 was dissolved in 77.0 mL of DMF.  
0.904 g (13.9 mmol) of NaN3 was added and the reaction vessel was stirred at 
room temperature overnight.  DMF was removed by distillation to yield a brown 
residue which was dissolved in methylene chloride and extracted with saturated 
brine solution.  The organic layer was dried with MgSO4, filtered and 
concentrated to give (2.21 g 92.0% yield) of the title compound 2-4.  1H NMR 
(200 MHz, CDCl3) d δ 0.910 (t, J=6.96 Hz, 12 H) 1.21 - 1.47 (m, 24 H) 2.24 (q, 
J=8.42 Hz, 8 H) 4.33 (s, 8 H) 4.39 (d, J=6.96 Hz, 4 H) 4.78 (t, J=8.24 Hz, 4 H) 
5.94 (d, J=6.96 Hz, 4 H) 7.15 (s, 4 H);  13C NMR (50 MHz, CDCl3) d δ 14.3, 22.8, 
27.7, 30.2, 32.1, 37.1, 45.3, 99.9, 120.9 , 122.4, 138.3, 153.9 
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C-Pentyltetraphenyl-1,2,3-triazole resorcin[4]arene[2-5] 
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Compound 2- 5 
 
0.100 g (0.010 mmol) of tetraazide 2-4, phenyl acetylene 0.049 g (0.483 mmol) 
and copper(I)iodide 0.002 g (0.001 mmol) was added to sealable reaction 
container.  The reaction contents were degassed by freeze-pump-thaw and 
allowed to stir overnight at room temperature.  After monitoring by TLC 4:1 
Hexane:Ethyl Acetate the reaction contents were transferred to a separtory 
funnel and extracted with ammonium chloride.  The organic and aqueous layers 
were separated and the organic layer was dried with magnesium sulfate, filtered, 
and concentrated.  The crude was purified via column chromatography 4:1 
hexane:ethyl acetate to give (0.070 g 50% yield) of the title compound 2-5.  1H 
NMR (400 MHz, CDCl3)   δ 0.900 (t, J=7.05 Hz, 12 H) 1.30 - 1.47 (m, 24 H) 2.25 
(q, J=10.3, 8.61 Hz, 8 H) 4.41 (d, J=7.14 Hz, 4 H) 4.79 (t, J=8.06 Hz, 4 H) 5.30 
(s, 8 H) 5.82 (d, J=7.51 Hz, 4 H) 7.25 (s, 4 H) 7.27 - 7.33 (m, J=7.51 Hz, 4 H) 
7.36 (t, J=7.87 Hz, 8 H) 7.76 (s, 4 H) 7.82 (d, J=7.33 Hz, 8 H) 13C NMR (50 MHz, 
CDCl3)   δ 14.1, 22.7, 27.5, 30.2, 32.0, 37.0, 43.6, 44.7, 99.5, 120.7, 121.4, 
125.8, 128.1, 128.7, 130.5, 138.1, 147.7, 153.8 
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.Phenyl 4-bromobenzenesulfonate[2-6] 
 
Br
SO O
O
 
Compound 2- 6 
 
To a round bottom flask sulfonyl chloride 0.500 g (1.96 mmol), phenol 0.220 g 
(2.30 mmol), triethyl amine 0.400 g (3.90 mmol) and 5.00 mL of methylene 
chloride was added.  The reaction was allowed to stir at room temperature for 3 
hours and 2.50 M HCl was added to reaction solution.  The solution was 
transferred to separtory funnel and extracted with diethyl ether.  The organic and 
aqueous layers were separated and the organic layer was extracted twice with 
2.50 M HCl.  The organic layer was dried with magnesium sulfate, filtered, and 
concentrated.  The crude was purified by recystallization from diethyl ether and 
hexane to give (0.599 g 98% yield) of the title compound 2-6.1H NMR (400 MHz, 
CDCl3)   δ 6.95 - 7.04 (m, 2 H) 7.21 - 7.36 (m, 3 H) 7.61 - 7.73 (m, 4 H) 
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.Phenyl 4-ethynyltrimethylsilanebenzenesulfonate[2-7] 
 
SO O
O
Si
 
Compound 2- 7 
To a sealable tube phenyl 4-bromobenzenesulfonate 2-6 0.580 g (1.84 mmol), 
PdCl2(PPh3)4 0.065 g (0.092 mmol), copper(I) iodide 0.018 g (0.092 mmol), 
diisopropyl amine 2.20 g (22.0 mmol), and tms-acetylene 0.217 g (2.20 mmol) 
was added.  The reaction was degassed by freeze-pump-thaw and heated to 
65oC for 8 hours.  Methylene chloride was added to the reaction vessel and 
transferred to a reaction vessel.  The organic layer was extracted with 
ammonium chloride and brine solution was then dried with magnesium sulfate, 
filtered, and concentrated.  The crude product was purified via column 
chromatography to givle (0.53 g, 87% yield) of the title compound 2-7. 1H NMR 
(200 MHz, CDCl3)   δ 0.21 - 0.35 (m, 9 H) 6.91 - 7.03 (m, J=1.83 Hz, 2 H) 7.23 - 
7.39 (m, 3 H) 7.52 - 7.64 (m, J=8.79 Hz, 2 H) 7.76 (d, J=8.79 Hz, 2 H) 
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Phenyl 4-ethynylbenzenesulfonate[2-8] 
SO O
O
 
Compound 2- 8 
 
0.660 g (2.01 mmol) phenyl 4-trimethylsilanebenzenesulfonate and 2.00 mL of 
the THF was added to a round bottom flask. Tetra-butyl ammonium fluoride 
(0.790 g 3.03 mmol) was added to the solution.  The reaction was allowed to stir 
for one hour at room temperature.  The solution was then passed through a silica 
plug with methylene chloride to give (0.520 g 55% yield) of the title compound 2-
8 1H NMR (200 MHz, CDCl3)   δ 3.32 (s, 1 H) 6.94 - 7.04 (m, 2 H) 7.23 - 7.39 
(m, 3 H) 7.57 - 7.66 (m, J=8.79 Hz, 2 H) 7.79 (d, J=8.79 Hz, 2 H) 
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Silane - 3-(3,3-dimethylbut-1-yn-1-yl)pyridine[2-9] 
N
Si
 
 
Compound 2- 9 
 
Bromopyridine 4.00 g (25.3 mmol), PdCl2(PPh3)4 0.890 g (1.30 mmol), CuI 0.241 
g (1.27 mmol), TMS-acetylene 2.98 g (30.4 mmol), and diisopropyl amine 31 
(304 mmol) was charged to a sealable tube.  The reaction vessel was degassed 
by freeze-pump-thaw and heated to 70oC for 8 hours.  The reaction allowed to 
reach room temperature and methylene chloride was added to the reaction 
vessel.  The organic layer was extracted with ammonium chloride, brine and 
dried with magnesium sulfate, filtered and concentrated.  The crude product was 
purified via column chromatography to give 3.81 g (85% yield) of the title 
compound 2-9.  1H NMR (200 MHz, CDCl3)   δ 0.19 - 0.32 (m, 9 H) 7.20 - 7.25 
(m, 1 H) 7.68 - 7.83 (m, 1 H) 8.53 (dd, J=4.94, 1.65 Hz, 1 H) 8.70 (d, J=2.20 Hz, 
1 H) 13C NMR (50 MHz, CDCl3)   δ -0.18, 122.9, 138.8, 148.7, 152.6 
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.3-ethynylpyridine[2-10] 
 
N
 
Compound 2- 10 
3-[2-Trimethylsilyl ethynl]-pyridine 2-9 0.698 g (3.98 mmol), 0.45 g (7.96 mmol) 
10.0 mL of methanol and 5.00 mL of methylene chloride was added to round 
flask.   The reaction was allowed to stir at room temperature for 3 hours.  The 
reaction was quenched with water and extracted with methylene chloride.  The 
organic layer was dried with magnesium sulfate, filtered and concentrated.  The 
crude was passed through a silica plug with methylene chloride to give (0.366 g 
89%) of the title compound 2-10.  1H NMR (200 MHz, CDCl3)   δ 3.22 (s, 1 H) 
7.20 - 7.32 (m, 1 H) 7.73 - 7.83 (m, 1 H) 8.57 (dd, J=4.94, 1.65 Hz, 1 H) 8.73 (d, 
J=2.20 Hz, 1 H) 13C NMR (101 MHz, CDCl3) d δ 80.6, 123.1, 139.1, 149.2, 152.8  
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.A,C Bis-1,2,3, triazole 3-pyridine resocinarene[2-11] 
OO O
OO
O O O
C5H11
C5H11C5H11 C5H11
H
HH
H
N3
N
N
N
N
N3
N N
N
N
 
Compound 2- 11 
Tetra-azide cavitand 2-4 (2.00 g 1.93 mmol), (0.438 g, 4.25 mmol) of 3-ethyl 
pyridine 2-10, (.037 g 0.190 mmol) of CuI, and 5.00 mL of dry THF was placed 
into a sealed tube.  The reaction vessel was degassed by freeze-pump-thaw and 
the reaction was allowed to stir overnight.  The reaction monitored by TLC 91:9 
chloroform:methanol.  Methylene chloride and a saturated ammonium chloride 
solution were added to the reaction solution.  The organic and aqueous layers 
were separated.  The organic layer was dried with MgSO4, filtered, and 
concentrated.  The resulting residue was purified via column chromatography. A 
gradient was applied starting with 50:50 hexane:ethyl acetate. Then slowly a 
gradient was ran from 98:2 chloroform:methanol to 91:9  chloroform:methanol.  
The desired A,C 1.2.3 triazole was isolated  to give (0.125g 5% yield ) of the title 
compound 2-11 1H NMR (400 MHz, CDCl3)   δ 0.91 (t, J=6.64 Hz, 12 H) 1.31 - 
1.45 (m, 24 H) 2.16 - 2.32 (m, 8 H) 4.31 (s, 4 H) 4.42 (d, J=7.03 Hz, 4 H) 4.80 (t, 
J=7.61 Hz, 4 H) 5.41 (s, 4 H) 5.91 (d, J=6.64 Hz, 4 H) 7.18 (s, 2 H) 7.25 (s, 2 H) 
7.86 (s, 2 H) 8.24 (s, 2 H); 13C NMR (101 MHz, CDCl3)   δ 14.4, 22.4, 27.8 , 29.9 
,32.2, 36.7, 44.7, 45.4, 99.8, 120.9, 122.0, 122.8, 133.2, 138.6, 139.1, 145.0, 
147.3, 150.0, 154.0 
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.A,C-Bis-1,2.3 triazole 3-pyridine-B,D-1,2,3-triazole phenyl 
benzene sulfonate[2-12] 
OO O
OO
O O O
C5H11
C5H11C5H11 C5H11
H
HH
H
N
N
N
N
N
N
N
N
N
N
N
N
N
N
S S
O
O
O
O
O O
Ph Ph
 
Compound 2- 12 
 
 
A,C bis-1,2,3 triazole 2-11 (0.061 g 0.049 mmol), phenyl 4 
ethynylbenzenesulfonate 2-8 (0.032 g 0.12 mmol) and CuI (0.001 g 0.005 mmol) 
and 0.500 mL of dry THF was added to a sealable vessel. The reaction vessel 
was degassed by freeze pump thaw.  The reaction was allowed to stir at room 
temperature overnight.  The reaction was monitored by TLC 91:9 
chloroform:methanol.  The reaction mixture was dissolved in methylene chloride 
and transferred to a separtory funnel. The organic layer was extracted with a 
ammonium chloride solution.  The organic and aqueous layers were separated.  
The organic layer was dried with magnesium sulfate, filtered and concentrated.  
The crude product was purified via column chromatography with a slow gradient 
from 100% chloroform to 91:9 chloroform:methanol to give (0.040g 46.0% yield) 
of title compound 2-12.  1H NMR (400 MHz, CDCl3)   δ 0.900 (t, J=7.03 Hz, 12 
H) 1.23 - 1.48 (m, J=6.64 Hz, 24 H) 2.17 - 2.32 (m, 8 H) 4.39 (d, J=7.42 Hz, 4 H) 
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4.80 (t, J=8.00 Hz, 4 H) 5.34 (d, J=13.7 Hz, 8 H) 5.33 (s, 4 H) 5.36 (s, 4 H) 5.82 
(t, J=7.03 Hz, 4 H) 6.92 - 7.06 (m, 4 H) 7.19 - 7.33 (m, 11 H) 7.80 (d, J=8.20 Hz, 
4 H) 7.88 (d, J=6.64 Hz, 4 H) 7.91 - 8.01 (m, J=8.59 Hz, 4 H) 8.19 (d, J=6.25 Hz, 
2 H) 8.54 (s, 1 H) 8.96 (s, 2 H) 13C NMR (101 MHz, CDCl3)   δ 14.4, 22.7, 27.5, 
30.1, 31.9, 37.0, 44.4, 99.4, 120.4, 120.5, 121.3, 121.6, 122.3, 126.1, 127.2, 
129.1, 129.7, 134.4, 136.3, 138.2, 138.3, 145.6, 149.6, 153.8, 153.9  
 
.A,B Bis 1,2,3, triazole 3-pyridine resorcin[4]arene[2-13] 
 
OO O
OO
O O O
C5H11
C5H11C5H11 C5H11
H
HH
H
N3
N
N
N
N
N3
N
N
N
N
 
Compound 2- 13 
Tetra-azide cavitand 2-4 (2.00 g 1.93 mmol), (0.438 g, 4.25 mmol) of 3-ethynl 
pyridine 2-10, (0.037g 0.190 mmol) of CuI, and 5.00 mL of dry THF was placed 
into a sealed tube.  The reaction vessel was degassed by freeze-pump-thaw and 
the reaction was allowed to stir overnight.  The reaction monitored by TLC 91:9 
chloroform:methanol.  Methylene chloride and a saturated ammonium chloride 
solution were added to the reaction solution.  The organic and aqueous layers 
were separated.  The organic layer was dried with MgSO4, filtered, and 
concentrated.  The resulting residue was purified via column chromatography. A 
gradient was applied starting with 50:50 hexane:ethyl acetate. Then slowly a 
gradient was ran from 98:2 chloroform:methanol to 91:9  chloroform:methanol.  
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The desired A,C 1.2.3 triazole was isolated to give (0.575 g 25.0% yield ) of the 
title compound 2-13.  1H NMR (200 MHz, CDCl3)   δ 0.85 - 1.00 (m, 12 H) 1.21 - 
1.50 (m, 24 H) 2.12 - 2.36 (m, 8 H) 4.23 - 4.29 (m, 4 H) 4.29 - 4.42 (m, J=7.33, 
7.33 Hz, 3 H) 4.48 (d, J=6.96 Hz, 1 H) 4.79 (t, J=8.06 Hz, 4 H) 5.33 - 5.47 (m, 4 
H) 5.84 (d, J=7.33 Hz, 3 H) 5.92 (d, J=6.96 Hz, 1 H) 7.18 (s, 1 H) 7.25 (s, 1 H) 
7.34 (dd, J=7.51, 4.58 Hz, 2 H) 7.80 - 7.94 (m, 2 H) 8.07 - 8.27 (m, J=8.06 Hz, 2 
H) 8.47 - 8.66 (m, J=4.40 Hz, 2 H) 8.96 (d, J=1.83 Hz, 2 H) 13C NMR (50 MHz, 
CDCl3)   δ 13.8, 14.7, 22.2,  23.4, 26.7, 28.4, 29.7, 31.6, 37.1, 44.1, 45.7 , 99.7, 
121.9, 122.5, 137.9, 138.1, 138.2, 138.4, 138.7, 154.0  
 
.A,B-Bis-1,2.3 triazole 3-pyridine-C,D-1,2,3-triazole phenyl 
benzene sulfonate[2-14] 
 
OO O
OO
O O O
C5H11
C5H11C5H11 C5H11
H
HH
H
N
N
N
N
N
N
N
N
N
N
NN
N
N
S
O
O
O
Ph
S
O
O
O Ph
 
Compound 2- 14 
A,B bis-1,2,3 triazole 2-13 (0.103 g 0.082 mmol), phenyl 4-
ethynylbenzenesulfonate 2-8 (0.053 g , 0.210 mmol) and CuI (0.002 0.008 mmol) 
and 1.00 mL of dry THF was added to a sealable vessel. The reaction vessel 
was degassed by freeze pump thaw.  The reaction was allowed to stir at room 
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temperature overnight.  The reaction was monitored by TLC 91:9 
chloroform:methanol.  The reaction mixture was dissolved in methylene chloride 
and transferred to a separtory funnel. The organic layer was extracted with a 
ammonium chloride solution.  The organic and aqueous layers were separated.  
The organic layer was dried with magnesium sulfate, filtered and concentrated.  
The crude product was purified via column chromatography with a slow gradient 
from 100% chloroform to 91:9 chloroform:methanol to give (0.050g 34.0% yield) 
for the title compound 2-14. 1H NMR (400 MHz, CDCl3)   δ 0.86 - 0.94 (m, 12 H) 
1.30 - 1.46 (m, 24 H) 2.25 (s, 8 H) 4.39 (qd, J=7.03 Hz, 4 H) 5.28 - 5.34 (m, 4 H) 
5.35 (s, 4 H) 5.70 - 5.91 (m, J=7.03, 7.03, 5.86, 5.86 Hz, 4 H) 6.98 (d, J=7.03 Hz, 
4 H) 7.80 (d, J=7.81 Hz, 4 H) 7.87 (s, 4 H) 7.94 (d, J=7.81 Hz, 4 H) 8.21 (s, 2 H)  
 
 
2.3-Reference: 
 
1. Cram D., K. S., Kim, H., Knobler, C., Maverick, E.,  Ericson, J.,  and  
Helgeson, R., Host-guest complexation. 46. Cavitands as open molecular 
vessels form solvates. Journal of American Chemical Society 1988, 110, 2229-
2237. 
2. Blokzijl, W., Engberts, J., Hydrophoic Effects. Opinions and Facts. Angew. 
Chem. Int. Ed 1993, 32, 1545-1579. 
3. Mezo, A. S., J., Water-Soluble Cavitands: Synthesis of Methylene-Bridged 
Resorcin[4]arene Containing Hydroxyls and Phosphate at Their Feet and 
Bromomethyls and Thiomethyls at Their Rims. Journal of Organic Chemistry 
1998, 63, 6824-6829. 
4. John R. Moran, S. K., and Donald J. Cram, Cavitands: synthetic molecular 
vessels. JACS 1982, 104, (21), 5826-5828. 
5. Kolb, C. F., G., Sharpless, B., Click Chemistry: Diverse Chemical Function 
from a Few Good Reactions. Angew. Chem. Int. Ed 2001, 40, 2004-2021. 
6. Braun, S., Kalinowski, H., Berger, S., 150 and More Basic NMR 
Experiments: A Practical Course. 1999. 
 
 
 
 
 
 
 
 
40 
Chapter 3  Thiophene Based Quadrupoles 
3.1,1-Introduction: 
 
 The synthesis of quadrupoles was addressed with thiophene-decorated 
cavitands. Longer feet were obtained by utilizing dodecanal in the acid 
condensation to improve solubility in non-polar solvents. Thiophenes were 
employed as linkers to place sulfonates and pyridiniums on the upper rim. The 
upper rim was functionalized with boronic acids in an alternate pattern and 
palladium catalyzed Suzuki cross coupling were utilized to functionalize the 
upper rim with 2-bromothiophenes.  The remaining arms are converted to iodides 
functionalized with palladium catalyzed Negishi cross coupling.  Titrations with 
chloroform were executed to transition from an 'open' state to an 'attractive' state.  
A dipole cavitand is also outlined to compare the energy to the quadrupole. 
Similar synthetic methods are utilized to synthesize the dipole.    
3.2-Synthesis of Quadrupole: 
 
A resorcin[4]arene based quadrupole is synthesized to study electrostatic 
interactions between sulfonates and pyridiniums. The quadrupole is unique due 
to the pattern of the cationic and anionic charges in a 
postive/negavtive/positive/negative orientation.  The use of a concave shaped 
molecule allows the for the measurement of intramolecular electrostatic 
attractions between the functional moieties on the upper rim of the 
resorcin[4]arene.  The main synthetic challenge is the positioning of the cations 
and anions on the upper rim of the resorcin[4]arene.  The main scaffold has been 
well established Cram1, 2, Rebek3, and Sherman4.  An acid catalyzed 
condensation between resorcinol and dodecyl aldehyde produces the 
dodecylcalix[4]arene 3-9. The use of dodecyl aldehyde was employed to 
increase solubility in non-polar solvents such as chloroform and carbon-
tetrachloride.  3-9 is treated N-bromo succinimide in methyl ethyl ketone to give 
3-10 via oxidative addition.  The phenolic seams of the octanol are stitched 
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together with bromochloro methane in the presence of potassium carbonate to 
give compound 3-11 tetra-bromo cavitand.  The tetra-bromo cavitand 3-11 is a 
starting material that is commonly utilized in many of the synthetic schemes for 
this research project. 
HO OH
HO OH
**
C11H23 C11 H23
4
HCl
Ethanol
C11H23
O
H
HO OH
**
C11H23 C11 H23
4
Br
O
N
O
O
Br
O O
*
C11H23 C11 H23
4
Br
OO
DMF
K2CO3
Br Cl
3-9
3-103-11  
Scheme 3.1 shows the synthesis of the tetra-bromocavitand. 
 
The key step is the fuctionalization of the tetra-bromo cavitand into an A,C  
pattern as shown in figure 3-1 for synthesizing a alternating pattern of 
cation/anion/cation/anion moieties on the upper rim of the cavitand.  Initially our 
focus was the synthesis of 1,2,3 triazoles with dodecyl chains for A,C 
functionalization as described in Chapter 2.  Sonogashira chemistry was 
employed on the upper rim of the cavitand with A,C-iodo-B,D-bromo cavitand. As 
shown in the scheme 3-2 below several attempts were made to purify the A,C-
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iodo-B,D-bromo cavitand from the A,B-iodo-C,D bromo cavitand (Figure 3-1).  
Unfortunately, the separation of these compounds was not successful while 
progression of the synthesis was not fruitful for the isolation the A,C cavitand 
from the A,B isomer.   
OO O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
OO O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
A,C Pattern A,B Pattern  
Figure 3.1 shows the A,C and A,B pattern of the upper arms.  
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Scheme 3.2 shows1,3 dipolar addition with dodecyl feet cavitand. 
 
The main challenges in isolating A,C iodo-B,D bromo cavitand was their small 
surface interaction with the silica gel for allowing separation of the two isomers.  
These compounds eluded with 95:5 Hexane: Ethyl Acetate.  The use of a boronic 
acid was employed to increase the polarity and yield an easier separation of the 
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A,C from the A,B cavitand.  With the addition of the boronic acids on the upper 
rim of the cavitand Suzuki chemistry was employed for  decorating the upper rim 
with pyridine and sulfonate moieties.  Thiophenes were selected due to synthetic 
precedence for functionalizing the 2 and 4 position for creating 2- bromo-4 
aromatic thiophenes5.  3-5 was synthesized by reacting 4-bromosulfonyl chloride 
with neopentyl alcohol in the presence of pyridine to give 3-36.  3-4 was achieved 
by a Suzuki cross-coupling with 2-thiophene boronic acid in presence of 
tetrakis(triphenylphosphine)palladium5.  3-4 was treated with bromine in 
methylene chloride to yield 2,2-dimethylpropyl 4-(5-bromo-2-
thienyl)benzenesulfonate 3-55.   
S
B(OH)2
Pd(PPh3)4
2M Na2CO3
Toluene
65oC
Br2
DCM
25oC
Br
SO O
Cl
OH
Br
SO O
O
SO O
O
S
SO O
O
S
Br
N
3-3 3-4 3-5  
Scheme 3.3  shows the synthesis of the bromo-thiophene sulfonate 
 
 3-(5-bromo-2-thienyl)pyridine 3-2 was prepared in a similar manner as the 
sulfonate thiophene.  2-thiophene boronic acid, 3-bromopyridine, 
tetrakis(triphenyl phosphine) palladium, sodium carbonate,  and toluene were 
placed together to give 3-1 via a cross-coupling5.  3-1 was treated with bromine 
to yield 3-2 in 83% yield5 (scheme 3-3). 
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S
B(OH)2
Pd(PPh3)4
2M Na2CO3
Toluene
65oC
N
Br
S N S N
Br
Br2
DCM
25oC
3-1 3-2  
Scheme 3.4 shows the synthesis of bromothiophene pyridine. 
 
The 3-(5-bromo-2-thienyl)pyridine 3-2 and 2,2-dimethylpropyl 4-(5-bromo-2-
thienyl)benzenesulfonate 3-5 are basic building blocks are utilized to 
functionalize the upper rim of resorcin[4]arene to synthesize a molecular 
quadrupole.  The pyridine moiety 3-2 can be alkylated to generate a cationic 
species and the 2,2 dimethylpropyl sulfonate 3-5 can be suponified to yield an 
anionic species.   
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Scheme 3.5 shows the synthesis of the bis-pyridine,bis-bromo cavitand. 
 
 3-11 was treated with 1.6 M n-butyl lithium in dry THF at -78oC then 
triisopropyl borate was added to solution to give 3-12 in 46% yield.  The bis-
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boronic acid was treated with 3-2 in toluene to give the A,C-bis thiophene 
pyridine resorcin[4]arene in 55% yield 4-10 (Scheme 3-4).   
4-10 was treated with 1.6 M n-butyl lithium in dry THF then triisopropyl 
borate to convert the remaining bromines to boronic acids. Unfortunately, the 
boronic acid was never isolated.  Concentration, time of reaction with n-butyl 
lithium, and equivalents of n-butyl lithium was varied.  Unfortunately, the bis-
boronic acid, bis-pyridine was never isolated.  Following the lithiation the 
electrophile was changed from triisopropyl boronate ester to iodine. The iodine 
gave a successful conversion from bromide to iodide but a poor yield of 17% was 
obtained (scheme 3-6).  
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Scheme 3.6 shows the conversion of the bromides to iodides on the upper rim. 
Interestingly, the n-butyl lithium alkylated the pyridine via a nucleophilic 
addition7.  An increase in the concentration of n-butyl lithium alkylated the 
pyridine more and decreased the yield of 3-14. The butyl chains were confirmed 
by 2-D NOESY8 from cross peaks from the butyl chains and the pyridines (figure 
3-2). 
46 
 
Figure 3- 2 shows a 2-D NOESY confirming the presence of butyl chains on the pyridines. 
 
pyridine aromatic and the alkyl chain of the butyl group.  To increase the yield 
butyl chains were decorated on the pyridines prior to the Suzuki cross-coupling.  
This was implemented to prevent the nucleophilic addition from occurring at other 
positions on the pyridine.  Unfortunately, upon the addition of the n-butyl lithium 
the alkylation still occurred.   
S
N
S
N
Br
Br2
DCM
25oC
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3-24
3-23
S
N
n-butyl lithium
THF
-78oC then 25oC
3-1  
Scheme 3.7 shows the synthesis of the bromothiophene pyridine with butyl chains. 
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  A solvent change from THF to diethyl ether and decreasing the 
concentration provided a 65% yield.  It is uncertain why the yield is increase but a 
solvent effect could be responsible for suppressing the nucleophilic addition.  The 
use of diethyl ether retards the nuclelophilic addition of the n-butyl lithium. 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H HH H
Br Br
S
S
N
N
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H HH H
I I
S
S
N
NBu
Bu
1)-78oC
n-butyl Lithium
Diethyl Ether
2) 1,2 diiodoethane
3)Na2SO4 (aqueous)
Bu
Bu
3-13
3-14  
Scheme 3.8 shows the optimized conversion of the bromide to iodide. 
 
The conversion of an aromatic bromide to an aromatic iodide allowed the 
use of Negishi chemistry9 to be employed.  3-13 was converted to 3-14 to 
accelerate the cross coupling for the addition of the 3-5 to the upper rim.  In 
previous synthetic schemes a phenyl-substituted sulfonate was utilized which 
was not compatible with n-butyl lithium.  Therefore, the use of a neo-pentyl 
protecting group was utilized which was compatible with n-butyl lithium at -78oC6.  
3-5 was treated with 1.6 M n-butyl lithium at -55oC inside of the cold well and a 
THF-zinc chloride solution was added to 3-5.  
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Scheme 3.9 shows the Negishi cross coupling with bis-iodo, bis-pyridine cavitnad. 
48 
 
Tetrakis(triphenylphosphine)palladium, zinc chloride tetrahydrofuran solution with 
3-5 and 3-14 was placed in a schlenck and heated at 70oC for 6 hours to give 3-
15 in 65 % yield.  To the best of my knowledge the use of a Negeshi cross-
coupling has never been employed to functionalize the upper rim of a 
resorcin[4]arene.   
 The alkylation of the pyridine was initially performed with methyl iodide 
with heating to 80oC.  This yielded mixtures of mono and bis-methylated products 
due to the steric hindrance of the butyl chains of the ortho-substituted nitrogen.  
A more aggressive agent methyl triflate was employed with is more reactive than 
methyl iodide.10  N-ethyldiisopropylamine was added to the solution to act as a 
buffer to remove any protonated pyridinium to give 3-16 in 55 % yield.   
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Scheme 3.10 shows the alkylation of the nitrogens and the removal of the neopentyl 
groups. 
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Next, the neo-pentyl groups were removed by heating tetra-methyl 
ammonium chloride and dimethylformamide to 150oC for 24 hours. The chloride 
ion displaces the neopentyl groups from the sulfonate.   After careful analysis, 
the 1H NMR spectrum indicates the methyl group at 4.3 ppm in compound 3-16 
was no longer present.  There is literature precedence that pyridinium chloride 
was used as a N-demethylation reagent via an Sn2 reaction11.   Lowering the 
temperature and utilizing lithium chloride in the place of tetramethyl ammonium 
chloride, the demethylation was controlled. This is the synthesis of the first 
resorcin[4]arene based quadrupole.   
 
.3.2,1-Synthesis of the A,B Model resorcin[4]arene [3-23]: 
 
The main synthetic challenge to model cavitand was the A,B bis-iodo 
resorcin[4]arene 3-19.  Two aromatic iodides directly adjacent to each other 
would allow for mono functionalization of the sulfonate and then the subsequent 
functionalization of the pyridine (scheme 3.11).  Negishi chemistry9 was 
employed as a synthetic method for functionalizating of the upper rim with 3-5 
and 3-24.  The first step involved the converting the tetrabromo 3-11 to the 
tetraiodo cavitand 3-18.  After drying 3-11 under high-vacuum, dry THF was 
added to the tetrabromocavitand 3-11 followed by the rapid addition of 1.6 M n-
butyl lithium to give the tetraiodo cavitand 3-18 in 50% yield.  The tetraiodo 
cavitand 3-18 was dried under high vacuum and treated with 1.1 equivalents of 
1.6 M n-butyl lithium then 1.1 equivalents of methanol.   
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Scheme 3.11 shows the synthesis of the bis, A,B iodo cavitand. 
 
Another equivalent of n-butyl lithium was added followed by an excess of 
methanol.  The resulting compound was purified by column chromatography to 
yield the A,B bis-iodo cavitand 3-19 in 15 % yield .  Negishi chemistry9 was 
employed to functionalize one of the iodides with 3-5 on the upper rim of the 
cavitand.  Using 1.2 equivalents of 3-5 yielded a mixture of the bis and mono 
functionalized sulfonate cavitands.  The mixture was purified via column 
chromatography generating the mono sulfonate 3-20 in 24 % yield. 2-
bromothiophene pyridine 3-2 was subjected to similar Negeshi conditions while 
this method produced the nucleophilc addition of the pyridine upon the addition of 
n-butyl lithium.  Yielding an unfruitful method for the addition of the pyridine onto 
the upper rim. Therefore, the 3-1 was treated with 1.6 M n-butyl lithium to 
generate 3-23 and subsequently brominated to give 3-24.  3-24 was placed in a 
cold well at -55oC and 1.6 M n-butyl lithium was added rapidly.  A zinc chloride 
solution was added to 3-24 and transferred to schlenck flask with 
tetrakis(triphenylphosphine)palladium and 3-20 to give 3-21 in 67% yield 
(scheme 3-12). 
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Scheme 3.12 functionalization of the model cavitand with Negishi chemistry. 
 
3-21 was treated with methyl triflate due to the steric for an ortho-substituted 
nitrogen to give 3-22 in 37% yield10.  3-22 was treated with tetramethyl 
ammonium chloride in dimethylformamide at 150oC for 24 hours and the methyl 
group at 4.3 ppm was no longer present.  With the addition of methyl triflate and 
N-ethyldiisopropylamine the desired 3-23 was achieved (scheme 3-13). 
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Scheme 3.13 shows the alkylation with methyl triflate and deprotection of the sulfonate. 
 
.3.3,1-Conformational Transition  
 
 It has been established that sulfonates and pyridiniums can attract to each 
other.  Schneider has measured sulfonate and pyridinium ion-pair complexes in 
water12.  As mentioned in chapter one of this thesis their studies of intermolecular 
ion pairs between sulfonate and pyridinium they found 5 + 1 kJ/mol.  The focus is 
to measure the attractive forces in an intramolecular system between sulfonate 
and pyridinium moieties.  The goal is to observe a transition between an ‘open 
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state’ and a ‘collapsed state’.   Conformational transitions such as the 
denaturation of proteins follow a two-state transition model.  To observe these 
transitions solvent plays a critical role in establishing the equilibrium between the 
‘open’ and ‘collapsed’ state.  Electrostatic forces are less attractive in polar 
solvents compared to non-polar solvents such as chloroform and carbon 
tetrachloride.   Solvents with high dielectric constants such dimethylsulfoxide and 
dimethylformaide can align between ion-pairs.  To observe the transition between 
'open' and 'close,' titrations are performed to observe the two-transition states.   
The quadrupole 3-17 and reference compounds 3-22 and 3-8 are titrated to 
measure the electrostatic forces between the sulfonate and pyridiniums on an 
intramolecular system.  To observe these transitions, chloroform is titrated into a 
dimethysulfoxide-d6 stock solution and monitored by 1H NMR.  Upon the 
addition of the chloroform-d to dimethylsulfoxide-d6 the change in chemical shift 
is monitored from 100% dimethylsulfoxide-d6 as chloroform-d is added.  As the 
concentration of dimethysulfoxide-d6 decreases, the chemical shift changes as a 
result.  Multiple spectrums are obtained at different concentrations of 
dimethylsulfoxide-d6 to chloroform-d.  These spectrums are stacked in order of 
increasing concentration of chloroform-d.  Monitoring the stacked spectrums 
peaks are analyzed by patterns.  Linear patterns are due to solvent effects while 
S-shaped patterns are potential transitions.  
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Compound Intermolecular or Intramolecular 
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Intramolecular 
Quadrupole cavitand 
  
Table 3.1 shows quadrupole cavitands and two reference compounds. 
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.3.3,2-Titrations 
 
Titrations were executed with chloroform-d and dimethylsullfoxide-d6 to 
observe the 'open' and 'attractive' states between the pyridinium and sulfonates.   
Chloroform-d was utilized as a non-polar media suitable for observing 
electrostatic interactions.  Dimethysulfoxide-d6  was utilized  as a polar media to 
disrupt the electrostatic interactions.  The use of 1H NMR spectroscopy was 
utilized to monitor the transition.  Initially, compounds 3-22 and 3-17 were 
dissolved in 100% dimethylsulfoxide-d6 and titrated with aliquots chloroform-d.    
Both products were titrated as stock solutions with equal concentrations for both 
solutions of dimethylsulfoxide-d6 and chloroform-d.  This was performed to 
observe a transition to determine the disassociation energies of sulfonates and 
pyridiniums.    After several titrations, the concentration domain of chloroform-d in 
dimethylsulfoxide-d6 was determined and careful titrations were attempted to 
observe the transition of 'open' and 'attractive.' The model compound was titrated 
with a 65%:35% chloroform-d:dimethylsulfoxide-d6 mixture and .05 mL of a 
chloroform stock solution was added to the NMR tube.  The peak at 9.4 ppm  
which is a singlet from the pyridinium shows a solvent effect moving to the left 
but a sharp kink is observed, which identifies a transition has occurred.   
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
.
8
8
5
0
.
8
9
8
1
.
0
2
9
1
.
2
7
3
1
.
4
6
0
1
.
4
8
5
1
.
5
0
4
1
.
5
2
3
1
.
5
4
1
1
.
7
8
1
2
.
3
5
9
2
.
5
8
8
2
.
9
2
2
3
.
0
5
0
3
.
4
0
5
3
.
4
2
5
3
.
9
4
1
4
.
3
8
2
4
.
4
0
14
.
4
1
9
4
.
7
7
5
4
.
7
8
6
4
.
8
2
0
4
.
8
3
8
5
.
3
2
4
5
.
7
2
1
5
.
7
3
3
5
.
7
5
0
5
.
7
5
8
5
.
7
7
6
5
.
7
8
9
6
.
4
8
9
6
.
5
1
4
7
.
1
9
4
7
.
3
0
1
7
.
4
1
0
7
.
4
1
4
7
.
4
2
4
7
.
5
3
7
7
.
6
5
6
7
.
7
0
5
7
.
8
2
8
7
.
8
4
8
7
.
8
7
2
7
.
8
9
4
8
.
5
1
0
9
.
4
4
9
Titration of 3 -22
65:35 CDCl 3 : DMSO
 
Increasing 
Concentration of 
Chlorform-d
65%:35% 
DMSO-d6 : CDCl3-d
.05 mL increament addtions
1H titration of 3-22 starting 65% DMSO-d6
Pyridinium Bridges
Methyl
from pyridinium
 
Figure 3.3 shows the NMR titration of 3-23 with bottom spectrum 65% chloroform-d with 
increasing concentration of chloroform of .05 mL with stacked spectrums. 
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The NMR spectrums are stacked on top of each other with the each spectrum 
referenced to trimethylsilane.   The pyridinium peak is monitored for a transition 
and the chemical shifts are recorded in excel against the concentration of the 
chlorform-d.  As shown in the excel plot below a transition occurs at 70% CDCl3 
suggesting the onset of conformational change of an open state to a closed state 
between the sulfonate and pyridinium capsules.   
The transition was examined by relating the kink to ΔG= RT ln K.  With K 
being the equilibrium constant for 'open' vs. 'attractive.'  Solvent effects are 
determined by linear relationship between change in chemical shift and 
concentration of chloroform in the stacked 1H NMR spectrums.  The kink is 
identified as a potential transition of 'open' to 'attractive.'   Upper and lower 
plateaus are identified as  ‘open’ for 0% to 65% chloroform-d.  In the range of 
85% to 100% chloroform-d are identified as 'attractive'.  With the upper and lower 
plateaus identified the kink is identified as the onset of a transition.  Each data 
point within the kink is quantified as a percentage of 'open' vs. 'attractive.'  This 
ratio is quantified as the equilibrium value for a disassociation constant for  'open' 
and 'attractive.'  The equilibrium value is then utilized in the ΔG= RT ln K to 
provide a ΔG value for 100% chloroform.   A linear extrapolation to the 'y' axis for 
100% chloroform provides a ΔG value for attractive state.  The extrapolation to 
100% chloroform identifies the point in which equilibrium is more pronounced for 
the  'attractive' state.  The linear extrapolation to 100% CDCl3  gives a ΔG of 5.1 
Kcal/mol for 3-22.  
 The same method was performed for the quadrupole 3-17 to determine the 
ΔG.   To map out the onset of a transition, 3-17 was dissolved in 100% 
dimethylsulfoxide-d6 and aliquots of chloroform-d were added.   The 
concentration of 3-17 is equal the stock solutions that were made.   After 
surveying from 100% dimethylsulfoxide-d6 to 80% chloroform-d, no transitions 
were observed by 1H NMR.   At higher concentrations of chloroform (>75%) the 
quadrupole was insoluble in the media.  This was determined by a precipitation 
that occurred and poor quality 1H NMR spectrums were obtained in this 
concentration domain.  
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Figure 3.4 shows the titration of the dipole 3-22 from 60% to 85% CDCl3  monitoring the 
change in chemical shift of the  pyridinium peak at 9.5 ppm 
 
 
 
58 
 
Figure 3.5 shows a solvent dependent-conformational change that is linear.  
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Figure 3.8 shows the titration of the quadrupole 
59 
 
Figure 3.7 shows the titration  of the quadrupole 3-17 from 50% chloroform to 85% 
chloroform-d. 
 
 
Compound  ΔG kcal/mol 
Quadrupole (3-17)  No transition 
Dipole (3-22) 5.1 kcal/mol 
 
 
3.4-Conclusions and Outlook 
 
Synthesized was a molecular quadrupole based resorcin[4]arene.  Suzuki 
and Negishi cross couplings were utilized to decorate the upper rim of the 
cavitand.  A model dipole was also synthesized as a reference to compare ΔG 
values.  Titrations were performed by titrating dimethylsulfoxide-d6 with 
chloroform-d.  The monopole showed a transition between 75% and 80% 
chloroform while the quadrupole did not show a clear titration.  Solubility problems 
occurred with quadrupole with 75% chloroform in dimethylsulfoxide.  The poor 
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solubility of the quadrupole in chloroform made it difficult to observe a transition 
for the quadrupole.   
3.5-Future Studies 
 
A practical method for the synthesis of a molecular quadrupole has been 
established.  Unfortunately, poor solubility of quadrupole in chloroform was 
found.  Titrations with other non-polar solvents can be employed such as 
methylene chloride-d2 and tetrahydrofuran-d6.   Ortho to the pyridine are butyl 
chains from nucleophilic attack from the n-butyl lithium.  The use of a longer alkyl 
chain could improve solubility.  For example, employing dodecyl lithium in the 
place of n-butyl lithium could increase the solubility of the quadrupole in non-
polar solvents.  
S N
Br
C10H21
 
Figure 3.9  shows the use of longer alkyl chains on the pyridine to increase solubility. 
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3.5-Experimental 
3-(2-thienyl)pyridine [3-1]5 
 
S N
 
compound 3- 1 
To a reaction vessel 3- bromo-pyridine (1.01g, 6.42 mmol, 0.619 mL), 2-
thiophene boronic acid (0.685 g, 5.35 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.310 g, 0.268 mmol), 2.00 M sodium 
bicarbonate (6mL), and toluene(13mL) were added.  The reaction vessel was 
degassed by freeze-pump-thaw.  The reaction was heated at 80o C for 10 hours. 
The solution was allowed to reach room temperature and a saturated sodium 
bicarbonate solution was added.  Methylene chloride was added and the 
aqueous and organic layers were separated.  The organic layer was dried with 
magnesium sulfate, filtered, and concentrated.  The product was isolated by 
column chromatography with 3:1 hexane: ethyl acetate to yield a light brown oil 
of 1 g (80% yield) of the title compound 3-1 5 1H  NMR (400 MHz, CDCl3)   δ 
7.12 (dd, J=4.29 Hz, 1 H) 7.30 (dd, J=7.22, 4.88 Hz, 1 H) 7.36 (d, J=3.90 Hz, 2 
H) 7.86 (d, J=8.20 Hz, 1 H) 8.51 (d, J=4.69 Hz, 1 H) 8.89 (d, J=1.95 Hz, 1 H); 13C 
NMR (101 MHz, CDCl3)   δ 123.6, 124.1, 125.9, 128.2, 130.3, 132.9, 140.4, 
147.0, 148.4  
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3-(5-bromo-2-thienyl)pyridine [3-2]5 
 
S NBr
 
compound 3- 2 
 
The reaction vessel was wrapped in foil to prevent exposure to light. Compound 
(3-1) 3-(2-thienyl)pyridine (4.36 g, 27.1 mmol) was dissolved in DCM (91.0 mL). 
A solution of bromine (1.81 mL, 35.0 mmol) in dichloromethane (45.0 mL) was 
added drop wise over 30 min. The reaction was stirred at ambient temperature 
for 2 hrs. A 1.00 M aqueous solution of sodium carbonate (30.0 mL) was added, 
and the mixture was stirred. The layers were separated. The aqueous phase was 
extracted with additional dichloromethane (30.0 mL). The combined organic 
layers were dried over Na2SO4, filtered, and concentrated to give 5.87 g (90% 
yield) of of the title compound 3-2.5 1H NMR (400 MHz, CDCl3) δ 7.057 (d, J=3.55 
Hz, 1 H) 7.08 - 7.11 (m, J=3.81 Hz, 1 H) 7.29 (dd, J=7.86, 7.48, 5.20, 4.06 Hz, 1 
H) 7.71 - 7.78 (m, J=2.28 Hz, 1 H) 8.53 (dd, J=4.82, 1.52 Hz, 1 H) 8.783 (d, 
J=1.78 Hz, 1 H); 13C NMR (50 MHz, CDCl3)   δ 112.7, 123.6, 124.4, 129.5, 
131.0, 132.6, 141.7, 146.5, 148.7  
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2,2-dimethylpropyl 4-bromobenzenesulfonate [3-3]6 
S
O O
O
Br  
compound 3- 3 
4-bromo-sulfonyl chloride 0.660 g (2.60 mmol), neopentyl alcohol 0.230 g (2.60 
mmol) and 26.0 mmol (2.00 mL) of pyridine was added to a round-bottom flask.  
The pyridine was removed in vacuo and the remaining contents were dissolved 
in diethyl ether 10.0 mL.  The ether was washed with 2.50 M HCl (15.0 mL).  The 
organic and aqueous layers were separated and the organic layer was washed 
again with 2.50 M HCl.  The organic layer was separated dried with magnesium 
sulfate, filtered, and concentrated.  The crude was dissolved in diethyl ether and 
layered with hexane to induce precipitation of needle-like crystals of the title 
compound 3-3  (0.662 g, 83% yield). 1H NMR (400 MHz, CDCl3)   δ 0.88 - 0.94 
(m, 9 H) 3.70 (s, 2 H) 7.69 - 7.73 (m, J=8.20 Hz, 2 H) 7.75 - 7.80 (m, J=8.20 Hz, 
2 H) 13C NMR (101 MHz, CDCl3)   δ 26.2, 31.9, 80.1, 129.0, 129.5, 132.7, 135.3 
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2,2-dimethylpropyl 4-(2-thienyl)benzenesulfonate [3-4]5 
SO O
O
S
 
compound 3- 4 
 
 
To a sealable reaction vessel, 2,2-dimethylpropyl 4-bromobenzenesulfonate 3-3 
(0.580 g, 1.89 mmol), 2-thiophene boronic acid (0.220 g, 1.72 mmoles), and 
tetrakis(triphenylphosphine)palladium(0) (0.080 g, 0.070 mmol), 2.00 M sodium 
bicarbonate (2.10 mL) and toluene (4.00 mL) were added.  The reaction vessel 
was degassed by freeze-pump-thaw.  The reaction was heated for 10 hours at 
70oC. The reaction was quenched by the addition of a saturated sodium 
bicarbonate solution. The aqueous layer was extracted with methyl chloride and 
the organic layer was dried with magnesium sulfate, filtered and concentrated.  
The product was isolated by column chromatography with 4:1 hexane:ethyl 
acetate to produce a white solid  of the title compound 3-4 (0.310 g, 57% yield).5 
1H NMR (400 MHz, CDCl3)   δ 0.91 (s, 9 H) 3.70 (s, 2 H) 7.14 (dd, J=3.90 Hz, 1 
H) 7.41 (dd, J=5.08, 1.17 Hz, 1 H) 7.45 (dd, J=3.90, 1.17 Hz, 1 H) 7.76 (d, J=8.59 
Hz, 2 H) 7.89 (d, J=8.20 Hz, 2 H); 13C NMR (101 MHz, CDCl3)   δ 26.2, 31.9, 
79.9, 125.5, 126.2, 127.3, 128.7, 128.8, 134.4, 139.7, 142.1 
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Dimethylpropyl 4-(5-bromo-2-thienyl)benzenesulfonate[3-5] 
SO O
O
S
Br  
compound 3- 5 
The reaction vessel was wrapped in foil to prevent exposure to light. Compound 
2,2-dimethylpropyl 4-(2-thienyl)benzenesulfonate 3-4 (0.260 g, 0.850 mmol) was 
dissolved in DCM (3.00 mL). A solution of bromine (0.050 mL, 1.02 mmol) in 
dichloromethane (1.40 mL) was added drop wise over 30 min. The reaction was 
stirred at ambient temperature for 2 hours. A 1.00 M aqueous solution of sodium 
carbonate (5.00 mL) was added, and the mixture was stirred. The layers were 
separated and the aqueous phase was extracted with additional dichloromethane 
(15.0 mL). The combined organic layers were dried over Na2SO4, filtered, and 
concentrated to give 0.320 g (96% yield) of the title compound 3-5.5 1H NMR 
(400 MHz, CDCl3)   δ 0.86 - 0.95 (m, 9 H) 3.71 (s, 2 H) 7.09 (d, J=3.90 Hz, 1 H) 
7.20 (d, J=3.90 Hz, 1 H) 7.62 - 7.70 (m, J=8.59 Hz, 2 H) 7.90 (d, J=8.20 Hz, 2 H);  
13C NMR (101 MHz, CDCl3)   δ 25.3 - 27.3, 31.9, 80.0, 114.3, 125.6, 125.9, 
128.9, 131.6, 134.9, 138.8, 143.4  
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3-(5-bromo-2-thienyl)pyridine [3-6] 
S N
C12H25
Br
I
 
compound 3- 6 
 
3-(5-bromo-2-thienyl)pyridine (3-2) (0.220 g, 0.920 mmol) was placed into a 
round bottom flask with 1-Iodododecane (0.410g, 1.40 mmol) neat.  The reaction 
was allowed to stir overnight at room temperature.  The reaction solution was 
dissolved in hexane and the solvent was decanted.  This was repeated twice to 
yield 3-(5-bromo-2-thienyl)-1-dodedecanylpyridinium iodide a brown oil (0.416 g, 
85% yield) of the title compound 3-6. 1H NMR (400 MHz, CDCl3)   δ 0.87 (t, 
J=6.64 Hz, 3 H) 1.17 - 1.50 (m, 20 H) 2.01 - 2.12 (m, J=7.03 Hz, 2 H) 5.06 (t, 
J=7.42 Hz, 2 H) 7.12 (d, J=3.90 Hz, 1 H) 7.98 (d, J=3.90 Hz, 1 H) 8.16 (dd, 
J=8.20, 6.25 Hz, 1 H) 8.52 (d, J=8.20 Hz, 1 H) 9.15 (d, J=5.86 Hz, 1 H) 9.85 (s, 1 
H);  13C NMR (101 MHz, CDCl3)   δ 13.9, 22.4, 25.7, 28.9, 29.1, 29.2, 29.3 - 
29.5. 31.6, 31.8, 61.8, 116.9, 128.6, 130.0, 132.1, 134.0, 135.8, 140.0, 140.3, 
141.9 
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Potassium 4-(5-bromo-2-thienyl)benzenesulfonate [3-7] 
 
SO O
O
S
Br
K
 
compound 3- 7 
Phenyl 4-(5-bromo-2-thienyl)benzenesulfonate  (0.520 g, 1.31 mmol), 10.0 mL of 
CH2Cl2 and 10.0 mL of methanol was placed into a small round bottom flask.  
0.730 g (13.0 mmol) of KOH was dissolved in 5.00 mL of CH3OH. The reaction 
was cooled to 0oC and slowly the KOH solution was added. A precipitate was 
filtered to produce 0.435 g (1.22 mmol, 93% yield) of the title compound 3-7. 1H 
NMR (200 MHz, DMSO-d6) d δ 7.26 (d, J=3.66 Hz, 1 H) 7.39 (d, J=3.66 Hz, 1 H) 
7.60 (d, J=8.42 Hz, 4 H) 13C NMR (101 MHz, DMSO-d6) d δ 110.8, 124.5, 124.7, 
126.4, 131.8, 132.7, 144.6, 147.9 
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3-(5-bromo-2-thienyl)-1-dodedecanylpyridinium-4-(5-bromo-2-
thienyl)benzenesulfonate [3-8] 
S
Br
N
C12H26 S
Br
S
O
O
O
 
compound 3- 8 
3-(5-bromo-2-thienyl)-1-dodedecanylpyridinium iodide 3-6 (0.086 g, 0.160 mmol) 
was dissolved in 1.00 mL of DMSO and the potassium 4-(5-bromo-2-
thienyl)benzenesulfonate 3-7 (0.057g, 0.160 mmol) was dissolved and 1.00 mL 
of DMSO.  The two solutions were then combined and the addition of water (1.00 
mL) produced the desired salt as an off white solid (0.090 g, 74% yield) of the 
title compound 3-8.    1H NMR (400 MHz, DMSO-d6)   δ 0.85 (t, J=6.83 Hz, 2 H) 
1.19 - 1.33 (m, 20 H) 1.95 (q, J=6.64 Hz, 2 H) 4.59 (t, J=7.61 Hz, 2 H) 7.25 (d, 
J=3.90 Hz, 1 H) 7.38 (d, J=3.90 Hz, 1 H) 7.47 (d, J=3.90 Hz, 1 H) 7.53 - 7.59 (m, 
J=8.59 Hz, 2 H) 7.59 - 7.64 (m, J=8.59 Hz, 2 H) 7.76 (d, J=3.90 Hz, 1 H) 8.15 
(dd, J=8.20, 6.25 Hz, 1 H) 8.76 (d, J=8.98 Hz, 1 H) 8.98 (d, J=6.25 Hz, 1 H) 9.43 
(s, 1 H); 13C NMR (101 MHz, DMSO-d6)   δ 13.8 - 14.2, 21.6 - 22.3, 25.2 - 25.6,  
28.3 - 28.5, 28.7 - 28.8, 28.7 - 28.8, 28.9 – 29.0, 28.9 - 29.1, 30.4 - 30.9, 31.3 , 
61.1, 110.8, 115.5, 124.8, 126.4, 128.3, 129.2, 129.3, 131.8, 132.4, 132.5, 132.7, 
133.0, 137.1, 140.5, 141.1, 142.9, 144.6, 148.0 
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C-dodecylcalix[4]resorinarene [3-9]13 
 
 
HOOH OH
OHHO
HO OH HO
C11H23
C11H23C11H23 C11H23
H HH
H
 
compound 3- 9 
 
A solution of 20.0 g (182 mmol) of resorcinol in 75.0 mL of ethanol and 25.0 mL 
of concentrated HCl was cooled to 0oC.  Dodecanal (33.5 g, 182 mmol) in 50.0 
mL of ethanol was added dropwise to the solution and stirred for 2 hour.  The 
solution was allowed to warm up to room temperature and heated to 75°C for 10 
hours.  The precipitate that was separated by filtration was washed repeatedly 
with water.  The crude solid was recrystallized from methanol to give the title 
compound 3-9 (48.5 g, 43.5 mmol). 1H NMR (400 MHz, acetone) δ ppm 0.90 (t, 
J=6.64 Hz, 12 H) 1.22 - 1.44 (m, 72 H) 2.29 (q, J=6.64 Hz, 8 H) 4.30 (t, J=7.81 
Hz, 4 H) 6.24 (s, 4 H) 7.54 (s, 4 H) 8.47 (s, 8 H) LRMS calc. for C72H112O8 found 
1106.0 (M + H2O )1123.0 
  
C-dodecyltetrabromocalix[4]resorinarene [3-10]13 
 
HOOH OH
OHHO
HO OH HO
C11H23
C11H23C11H23 C11H23
H HH
H
Br
Br Br
Br
 
compound 3- 10 
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C-dodecylcalix[4]resorinarene (50.0 g, 45.2 mmol) 3-9 and N-bromosuccinimide 
48.0 g (271 mmol) was added to a flask. Methyl Ethyl Ketone 2.60 L was added 
to the reaction and stirred at room temperature overnight.  The precipitate from 
the reaction was filtered and washed with cold methyl ethyl ketone, then cold 
water.  The remaining solvent was removed via high-vacuum to give 61.5 g (43.3 
mmol) of title compound 3-10. LRMS calculated for C72H108Br4O8 1416.48 found 
1421.7 
 
C-dodecyltetrabromorescorcin[4]arene [3-11] 13 
 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H HH
H
Br
Br Br
Br
 
compound 3- 11 
 
To a slurry of C-dodecyltetrabromocalix[4]resorinarene 3-10 (50.0 g, 35.0 mmol), 
potassium carbonate (68.0 g, 493 mmol), DMF 1350 mL and 
bromochloromethane (493 mmol, 33.0 mL) was added and the mixture was 
stirred at 65°C for three days under nitrogen. Every 24 hours more 
bromochloromethane (4.70 mL, 70.0 mmol) was added. The DMF was removed 
in vacuo to give a dark brown gum.  Diethyl Ether was added to the residue 
followed by 2.00M HCl, with stirring.  The aqueous phase was separated and 
extracted with more diethyl ether. The combined organic layers were washed 
with water and saturated brine, dried over magnesium sulfate and filtered. 
Evaporation of the solvent yielded a clear brown gum which was purified with 
column chromatography 9:1 hexane:ethyl acetate to produce the pure product as 
a light brown oil of the title compound 3-11.13 70% Yield 1H NMR (400 MHz, 
CDCl3)   δ 0.89 (t, J=6.64 Hz, 12 H) 2.20 (d, J=7.81 Hz, 8 H) 4.33 (d, J=7.42 Hz, 
4 H) 4.86 (t, J=8.00 Hz, 4 H) 5.98 (d, J=7.42 Hz, 4 H) 7.07 (s, 4 H); 13C NMR 
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(101 MHz, CDCl3)   δ 14.3 , 22.9, 27.9, 29.6, 29.9, 30.3, 32.1, 38.1, 93.2, 98.9, 
120.9, 138.9, 155.1, LRMS calculated for C76H108Br4O8 1464.48 (M+)1468.6 
(M+Na)1486.7 
 
 
 
A,C Bis-boronic acid- C,D-bis-bromo resocin[4]arene [3-12] 14 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H HH
H
Br
B(OH)2 B(OH)2 Br
 
compound 3- 12 
C-dodecyltetrabromorescorcin[4]arene 3-11 (4.10 g, 2.80 mmol) and dry THF 
(40.0 mL) was added to a sealed tube with a stir-bar.  The resulting solution was 
evaporated to dryness and heated to 80°C for one hour.  The vacuum was 
replaced with nitrogen and the procedure was repeated two more times.  Dry 
THF (200 mL) was added to the dried tetrabromo cavitand.  The reaction vessel 
was chilled to -78° C with a dry ice temperature bath and n-butyllithium (0.380 g, 
3.70 mL of 1.60 M in hexanes, 2.1 eqiv.). After 20 minutes of stirring, triisopropyl 
borate (4.20 g, 22.0 mmol, 5.20 mL) was added to the reaction vessel at - 78° C.  
After stirring for 30 minutes, 2.50 M of HCL was added to the reaction vessel and 
allowed a stir for an additional 30 minutes.  The reaction solution was transferred 
to a separtory funnel and methylene chloride and brine were added to the flask.  
The organic and aqueous layers were separated and the aqueous layer was 
washed a second time with methylene chloride.  The organic layers were 
combined, dried with magnesium sulfate, filtered and concentrated.  The 
resulting oil was purified by column chromatography with the product eluting with 
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50:50 hexane:ethyl acetate of the title compound 3-12 (1.82 g, 46% yield).14 1H 
NMR (400 MHz, CDCl3)   δ 0.89 (none, J=6.64 Hz, 8 H) 1.36 (q, 99 H) 2.23 (q, 
J=7.81 Hz, 8 H) 4.45 (d, J=7.42 Hz, 4 H) 4.81 (s, 3 H) 5.60 (s, 4 H) 5.90 (d, 
J=7.42 Hz, 4 H) 7.06 (s, 2 H) 7.20 (s, 2 H);  13C NMR (101 MHz, CDCl3)   δ 
14.3, 22.9, 28.0, 29.6, 29.9,  30.3, 32.1,  37.4, 98.9, 113.3, 118.8, 123.4, 138.1, 
139.2, 152.1, 158.6 
 
 
A,C Bis-thiophene pyridine- C,D-bis-iodo resocin[4]arene [3-13] 
 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H HH
H
Br Br
S
S
N
NBu
Bu
 
compound 3- 13 
 
 
 
The A,C bis boronic acid cavitand 3-12 (1.00 g, 0.715 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.083 g, 0.071 mmol), 5-(5-bromo-2-
thienyl)-2-butylpyridine(0.470 g, 2.14 mmol), 2.00 M sodium bicarbonate (1.50 
ml) and toluene (4.00 ml) was placed in a sealed tube. The reaction vessel was 
de-gassed by freeze-pump-thaw three times and heated for eight hours at 70°C.  
The reaction vessel was allowed to reach room temperature and the contents 
were washed with a saturated sodium bicarbonate solution. Methylene chloride 
was added and the organic layer was washed with a brine solution. The organic 
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layer was dried with magnesium sulfate, filtered and concentrated to yield a light-
brown residue. The product was isolated by column chromatography to yield the 
desired A,C-bis 5-(5-bromo-2-thienyl)-2-butylpyridine resorcin[4]arene  as a light 
brown residue (0.810 g, 65% yield) of the title compound 3-13. 1H NMR (400 
MHz, CDCl3)   δ 1.23 - 1.51 (m, 80 H) 2.27 (d, J=3.90 Hz, 8 H) 4.42 (d, J=7.42 
Hz, 4 H) 4.90 (t, J=8.00 Hz, 3 H) 5.85 (d, J=7.42 Hz, 4 H) 7.15 (s, 2 H) 7.19 (s, 1 
H) 7.20 (d, J=3.90 Hz, 1 H) 7.33 (dd, J=5.08 Hz, 2 H) 7.36 (d, J=3.51 Hz, 2 H) 
7.87 (dd, J=6.05, 2.15 Hz, 2 H) 8.54 (d, J=3.51 Hz, 2 H) 8.89 (d, J=1.95 Hz, 2 H); 
13C NMR (101 MHz, CDCl3)   δ 14.1, 22.7, 27.8, 29.4, 29.7, 30.2, 31.9, 37.4, 
99.5, 113.2, 119.0, 120.4, 122.2, 122.7, 123.6, 127.2, 129.9, 133.1, 138.5, 139.1, 
141.3, 146.2, 152.1 152.5 161.7  LRMS calculated for C102H136Br2N2O8S2  1738.8 
found (M+1)1742.9 
 
 
 
 
 
 
A,C Bis-thiophene pyridine- C,D-bis-iodo resocin[4]arene[3-14] 
 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H HH
H
I I
S
S
N
NBu
Bu
 
compound 3- 14 
The A,C bis-thiophene pyridine with butyl groups bis-bromo cavitand 3-13 (0.330 
g, 0.190 mmol) and 5.00 mL of dry diethyl ether was added into a sealable 
reaction vessel.  The solvent was evaporated to dryness and the remaining 
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residue was heated with an oil bath under high vacuum at 80°C for one hour.  
This step was repeated twice.  After drying, the substrate was suitable for metal 
halogen exchange. 20.0 mL of dry diethyl ether was added. After chilling to           
-78oC, (0.590 mL, 0.950 mmol) of n-butyl lithium 1.6 M in hexanes was added 
rapidly to the solution.  The reaction immediately turned a reddish color and was 
allowed to stir for 10 minutes.  Diiodoethane (0.375 g, 1.33 mmol) was added to 
the reaction vessel and immediately the solution turned dark brown.  20.0 mL of 
2.00 M sodoium thiosulfate solution was added and extracted with a 25.0 mL 
portion of methylene chloride.  The aqueous and organic were separated and the 
organic layer was washed with brine, dried with magnesium sulfate, filtered, and 
concentrated.  The crude product was purified by column chromatography with 
the desired product eluting with a gradient from 99:1 hexane:ethyl acetate to 3:1 
hexane:ethyl acetate, yielding a clear residue (0.230 g, 65% yield) of the title 
compound 3-14  1H NMR (400 MHz, CDCl3)   δ 0.88 (t, J=6.64 Hz, 12 H) 0.95 (t, 
J=7.42 Hz, 6 H) 1.24 - 1.50 (m, 98 H) 1.67 - 1.79 (m, J=7.42 Hz, 5 H) 2.26 (d, 
J=2.73 Hz, 8 H) 2.78 - 2.84 (m, J=7.81 Hz, 4 H) 4.36 (d, J=7.03 Hz, 4 H) 4.89 (t, 
J=8.20 Hz, 4 H) 5.85 (d, J=7.42 Hz, 4 H) 7.17 (s, 5 H) 7.19 (d, J=3.51 Hz, 2 H) 
7.30 (d, J=3.51 Hz, 1 H) 7.77 (dd, J=8.20, 2.34 Hz, 2 H); 13C NMR (101 MHz, 
CDCl3)   δ 13.9, 14.1, 22.4, 22.7, 27.8, 29.4, 29.6 - 29.9, 30.3, 31.9, 37.5, 37.77, 
92.8, 99.5, 120.3, 120.7, 122.1, 122.7, 123.6, 127.3, 130.0, 133.1, 133.2, 138.5, 
138.6, 141.3, 146.2, 152.4, 155.0, 161.8,  LRMS calculated for C102H136I2N2O8S2 
1834.8 found (M+H) 1840 
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A,C Bis-Thiophene pyridine-C,D Bis-thiophene 
dimethylpropylbenzenesulfonate[3-15] 
OO O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
S
S S S
N
N
S
O
O
O
S
O
OO
 
compound 3- 15 
 
 
The bis-pyridine bis iodo cavitand 3-14 (0.090 g, 0.050 mmol) was transferred to 
a sealable reaction vessel.  The dimethylpropyl 4-(5-bromo-2-
thienyl)benzenesulfonate 3-5 (0.060 g, 0.150 mmol) was pre-weighed into a vial 
and both reaction vessels were taken into a glove box.  In a cold well inside a 
glove box, a solution of compound A in 2.00 mL of dry THF was treated with n-
butyl lithium (0.100 mL, 0.160 mmol) at -55oC.   After 5 minutes of stirring, 0.060 
g (0.41 mmol) of zinc chloride solution was added to the reaction vessel and 
allowed to stir for five minutes.  The solution was transferred into the scklenk-
flask and (0.009 g, 0.008 mmol) of tetrakis(triphenylphosphine)palladium was 
added to the reaction vessel. The vessel was taken outside of the glove box and 
heated to 70° C for eight hours. The reaction was quenched with 2.00M HCl and 
extracted with 20.0 mL of methylene chloride.  The organic and aqueous layers 
were separated and the organic layer was washed with brine, dried with 
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magnesium sulfate, filtered and concentrated.  The crude oil was purified via 
column chromatography with a gradient from 99:1 hexane:ethyl acetate to 2:1 
hexane: ethyl acetate to produce the desired product as a clear oily residue 
(0.050 g, 52% yield) of the title compound 3-15. 1H NMR (400 MHz, CDCl3)   δ 
0.85 - 0.97 (m, 36 H) 1.23 - 1.53 (m, 90 H) 1.65 - 1.74 (m, J=7.61, 7.61 Hz, 4 H) 
2.28 - 2.37 (m, J=5.86 Hz, 8 H) 2.78 (t, J=7.81 Hz, 4 H) 3.68 (s, 4 H) 4.42 (d, 
J=7.03 Hz, 4 H) 4.94 (t, J=7.81 Hz, 4 H) 5.81 (d, J=7.42 Hz, 4 H) 7.15 (d, J=8.20 
Hz, 2 H) 7.23 - 7.25 (m, 3 H) 7.27 - 7.30 (m, 5 H) 7.39 (d, J=3.90 Hz, 2 H) 7.71 
(d, 4 H) 7.75 (d, J=2.34 Hz, 2 H) 7.87 (d, J=8.59 Hz, 4 H) 8.73 (d, J=2.34 Hz, 2 
H); 13C NMR (101 MHz, CDCl3)   δ 14.1, 14.3, 22.6, 22.9, 26.0 - 26.5, 28.1, 
29.6, 29.8 - 30.2, 30.8, 31.9, 32.1, 32.2, 37.4, 37.9, 79.9, 100.5, 120.5, 120.7, 
121.6, 121.9, 123.0, 123.8, 125.3, 126.2, 127.5, 128.8, 130.3, 130.5, 133.3, 
133.4, 134.5, 135.4, 138.7, 138.8, 139.3, 141.3, 142.3, 146.4, 152.5, 152.6, 
162.1, LRMS calculated  for C132H170N2O14S6 2199.1 found (M+H) 2201.3 
(M+Na) 2223.3 
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A,C Bis-Thiophene pyridinium triflate-C,D Bis-thiophene 
dimethylpropylbenzenesulfonate resorcin[4]arene[3-16] 
 
OO O
OO
O O O
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compound 3- 16 
 
0.051 g (0.023 mmol) of the tetrafuctionalized resorcin[4]arene 3-15, 0.019 g 
(0.116 mmol) of methyl triflate, and 1.00 mL of dry chloroform was transferred 
into a sealable reaction container.  A drop of N-ethyldiisopropylamine was added 
to the solution.  The reaction was allowed to stir overnight at room temperature.  
The solvent and excess methyl triflate was removed via high vacuum.  The crude 
was purified via column chromatography 92:8 chloroform:methanol to produce 
0.032 g (55% yield) of the title compound 3-16 1H NMR (400 MHz, CDCl3)   δ 
0.85 - 0.87 (m, 9 H) 0.87 - 0.92 (m, 24 H) 0.94 (t, 6 H) 1.25 - 1.51 (m, 90 H) 1.67 
- 1.75 (m, 4 H) 2.28 - 2.37 (m, J=6.64 Hz, 8 H) 2.95 - 3.01 (m, 4 H) 3.61 - 3.66 
(m, 4 H) 4.35 - 4.38 (m, 6 H) 4.41 (d, J=7.42 Hz, 4 H) 4.93 (t, J=7.81 Hz, 4 H) 
5.78 (d, J=7.03 Hz, 4 H) 7.25 (d, J=3.51 Hz, 2 H) 7.28 (s, 2 H) 7.30 - 7.34 (m, 
J=3.90 Hz, 4 H) 7.43 (d, J=3.90 Hz, 2 H) 7.64 (d, J=3.51 Hz, 2 H) 7.68 (d, J=8.59 
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Hz, 2 H) 7.72 (t, J=8.00 Hz, 4 H) 7.79 - 7.85 (m, 4 H) 8.27 - 8.36 (m, 1 H) 9.13 (s, 
2 H); 13C NMR (101 MHz, CDCl3)   δ 13.5, 14.1, 22.2, 22.7, 25.9, 28.0, 29.2, 
29.4, 29.6 - 30.0, 30.6, 31.6, 31.9 , 32.2 , 37.2, 45.9, 79.8, 100.2, 118.6, 120.3, 
120.9, 121.6, 121.8, 125.6, 125.9, 127.8, 128.0, 128.5, 130.5, 131.0, 132.9, 
133.6, 134.8, 135.0, 137.4, 138.3, 138.4, 139.4, 140.4, 141.9, 142.7, 152.4, 
152.5, 156.0, LRMS calculated for C134H176N2O14S6 2199.1 found (M+1) 2229.4 
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A,C Bis-Thiophene pyridinium C,D Bis-thiophene-
benzenesulfonate resorcin[4]arene[3-17] 
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compound 3- 17 
 
 
A,C Bis-Thiophene pyridinium triflate-C,D Bis-thiophene 
dimethylpropylbenzenesulfonate resorcin[4]arene[3-16] was placed in a schlenck 
flask with LiCl, and DMF.  The reaction was degassed and refilled with nitrogen.  
After heating for 16 hours at 130oC, the reaction was allowed to reach room 
temperature.  The solvent was removed under high-vacuum and the remaining 
residue was dissolved in methylene chloride.  After concentrating the methylene 
chloride, the residue was recystallized with methanol to produce the title 
compound 3-17. 1H NMR (400 MHz, DMSO-d6) δ ppm 0.87 (t, J=3.51 Hz, 12 H) 
0.97 (t, J=7.22 Hz, 6 H) 1.20 - 1.53 (m, 97 H) 1.64 - 1.75 (m, 8 H) 3.02 - 3.12 (m, 
J=7.42 Hz, 4 H) 4.27 - 4.32 (m, 6 H) 4.37 (d, J=6.64 Hz, 4 H) 4.83 (d, J=6.64 Hz, 
4 H) 6.02 (d, J=7.03 Hz, 4 H) 7.24 (d, J=3.90 Hz, 2 H) 7.30 (d, J=3.90 Hz, 1 H) 
7.41 (d, J=3.12 Hz, 1 H) 7.49 (d, J=3.90 Hz, 1 H) 7.57 (d, 2 H) 7.77 (d, J=3.90 
Hz, 2 H)  7.87 (m, 4 H)  8.04 (d, J=8.98 Hz, 4 H) 8.73 (d, J=8.20 Hz, 2 H) 99.32 
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(s, 2 H) Concentration in DMSO-d6 was too low to record 13C within 1d LRMS 
calc for C124H154N2O14S6 2088.9 found (M+) 2090.2 (M+Na) 211.2.1 
 
 
 
 
 
 
Tetraiodo resorcin[4]arene [3-18] 
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compound 3- 18 
 
Tetrabromo cavitand 3-11 (0.250 g, 0.170 mmol) was transferred to a schlenk 
flask.  2.00 ml of dry THF was added to vessel and evaporated to dryness.  The 
resulting residue was heated to 80oC for one hour under high vacuum. This step 
was repeated twice.  This provided suitable conditions for metal-halogen 
exchange.  5.00 mL of dry THF was added to the reaction vessel.  After chilling 
to -78oC, 0.530 mL (0.850 mmol) of 1.6 M n-butyl lithium in hexanes was added 
rapidly to the flask.  The reaction was allowed to stir for 30 minutes at -78 oC and 
0.259 g (1.02 mmol) of iodine was added to the reaction at -78 oC.  The contents 
were stirred for 10 minutes and the reaction was quenched with 15.0 mL of 2.00 
M sodium thiosulfate.  The product was extracted with 25.0 mL of methylene 
chloride and the layers were separated.  The organic layer was washed with 
saturated brine, dried with magnesium sulfate, filtered and concentrated.  The 
crude product was purified via column chromatography with a gradient from 99:1 
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hexane:ethyl acetate to 9:1 hexane:ethyl acetate to yield tetraiodo cavitand as a 
light-brown residue of the title compound 3-18 (0.140 g, 50% yield) 1H NMR (400 
MHz, CDCl3)   δ 0.89 (t, J=6.64 Hz, 12 H) 2.20 (d, J=7.81 Hz, 8 H) 4.33 (d, 
J=7.42 Hz, 4 H) 4.86 (t, J=8.00 Hz, 4 H) 5.98 (d, J=7.42 Hz, 4 H) 7.07 (s, 4 H) 
13C NMR (101 MHz, CDCl3)   δ 14.3 , 22.9, 27.9, 29.6, 29.9, 30.3, 32.1, 38.1, 
93.2, 98.9, 120.9, 138.9, 155.1 
 
 
 
A,B-bis-iodo-C,D-bis-hydrogen resorcin[4]arene [3-19]15 
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compound 3- 19 
 
Tetraiodo cavitand 3-18 (1.32 g, 0.796 mmol) was placed into a sealable reaction 
vessel and 10.0 mL of dry THF was added.  The THF was evaporated to dryness 
and heated to 80° C for one hour.  This step was repeated twice.  50.0 mL of dry 
THF was added.  After chilling to -78°C, 0.550 mL (0.880 mmol) of 1.6 M. n-butyl 
lithium in hexane was added rapidly and the reaction was stirred vigorously.   
After 30 minutes, 0.067 mL (0.876 mmol) methanol was added at -78° C and the 
solution was stirred for an additional 30 minutes.  0.550 mL (0.880 mmol) of 1.60 
M n-butyl lithium in hexane was added rapidly and the reaction was stirred 
vigorously. After 30 minutes, an excess of isopropanol was added to the reaction 
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solution.  The temperature was allowed to warm up room temperature and the 
solvent was removed via a rotatory evaporator.  The remaining residue was 
dissolved in diethyl ether and washed with brine.  The layers were separated and 
the organic layer was dried with magnesium sulfate, filtered and concentrated.  
The resulting crude product was purified via column chromatography with a 
gradient from 99:1 hexane:ethyl acetate to 92:8 hexane:ethyl acetate yielding a 
mixture of A,B and A,C bis-iodo-bis-hydrogen.  The A,B and A,C isomers were 
resolved by repeating the column with the same gradient from  99:1 hexane: 
ethyl acetate to 92:8 hexane:ethyl acetate to produce the A,B bisiodocavitand as 
an oily residue of the title compound 3-19 (0.168 g, 15% yield). 1H NMR (400 
MHz, CDCl3)   δ 0.88 (t, J=6.83 Hz, 12 H) 1.15 - 1.50 (m, 72 H) 2.21 (q, J=7.03 
Hz, 8 H) 4.29 (d, J=7.42 Hz, 1 H) 4.37 (d, J=7.42 Hz, 2 H) 4.46 (d, J=7.03 Hz, 1 
H) 4.65 - 4.90 (m, 4 H) 5.74 (d, J=7.42 Hz, 1 H) 5.85 (d, 1 H) 5.97 (d, J=7.42 Hz, 
1 H) 6.51 (s, 2 H) 7.08 (s, 4 H); 13C NMR (101 MHz, CDCl3)   δ 14.3, 22.9, 27.78 
- 28.2, 29.6, 29.7 - 30.4, 32.1, 36.5, 37.3, 38.1, 93.0, 99.0, 99.3, 99.6, 116.9, 
120.8, 120.9, 138.2, 138.9, 139.3, 154.8 154.9, 155.2, LRMS calculated for  
C76H110I2O8 1404.6 found (M+H) 1405.9 (M+H2O) 1422.9 
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Mono- thiophene-dimethylpropylbenzenesulfonate-mono-iodo-
bishydrogen resocin[4]arene[3-20] 
 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
H
H
I
S
SO O
O
 
compound 3- 20 
 
A,B bis iodo bis-hydrogen cavitand 3-19 (0.322 g, 0.229 mmol) was transferred 
to a sealable reaction container.  0.103 g (0.275 mmol) of dimethylpropyl 4-(5-
bromo-2-thienyl)benzenesulfonate was weighed into a vial.  Both containers were 
taken inside of a glove box and 3 mL of dry THF was added to the vial.  After 
chilling to -78°C, (0.200 mL, 0.320 mmol) n-butyl lithium 1.6 M in hexanes was 
added rapidly.  After 5 minutes of stirring, (0.156 g, 0.115 mmol) zinc chloride 
dissolved in 1.00 mL of dry THF was added to the reaction vessel.  The zinc 
species was transferred to the sealable reaction vessel and (0.026 g, 0.023 
mmol) tetrakis(triphenylphosphine)palladium(0) was added. The reaction 
container was taken out of the glove box and heated for 10 hours at 70°C. The 
reaction was allowed to reach room temperature and 15.0 mL of methylene 
chloride was added.  The product was extracted with 10.0 mL of saturated brine 
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solution and the layers were separated. The organic layer was dried with 
magnesium sulfate, filtered and concentrated. The crude product was purified via 
column chromatography with a gradient from 99:1 hexane:ethyl acetate to 4:1 
hexane:ethyl acetate as a clear oily residue of the title compound 3-20(0.100 g, 
28% yield) 1H NMR (400 MHz, CDCl3)   δ 0.82 - 0.98 (m, J=6.64 Hz, 21 H) 1.15 
- 1.52 (m, 70 H) 2.15 - 2.34 (m, 8 H) 3.66 - 3.76 (m, 2 H) 4.35 (dd, J=11.52, 7.22 
Hz, 1 H) 4.45 (dd, J=7.22, 3.71 Hz, 1 H) 4.69 - 4.90 (m, J=8.20, 8.20 Hz, 3 H) 
5.74 (dd, J=15.23, 7.03 Hz, 1 H) 5.85 (dd, J=16.59, 7.22 Hz, 1 H) 6.50 (s, 1 H) 
6.52 (s, 1 H) 7.12 - 7.16 (m, 2 H) 7.21 (d, J=3.90 Hz, 1 H) 7.43 (d, J=3.90 Hz, 1 
H) 7.74 (d, J=8.20 Hz, 1 H) 7.90 (d, J=8.59 Hz, 1 H) 13C NMR (101 MHz, CDCl3) 
d δ 14.1, 22.7, 26.0, 27.8, 27.9, 29.4, 29.7, 29.9, 30.0, 30.1, 30.2, 31.7, 31.9, 
36.3, 36.7, 37.2, 37.5, 79.7, 92.6, 99.2, 99.5, 99.5, 99.8, 116.5, 120.6, 120.7, 
120.8, 121.6, 125.1, 125.8, 128.6, 130.2, 134.1, 135.4, 137.8, 138.1, 138.4, 
138.6, 138.7, 138.9, 139.1, 139.2, 142.0, 152.2, 152.7, 154.8, 154.9, 155.0, 
155.1 
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A,B-Mono- thiophene-dimethylpropylbenzenesulfonate-mono-
thiophene-pyridine-bishydrogen resocin[4]arene[3-21] 
 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
H
H
S
SO O
O
S
N
Bu
 
compound 3- 21 
 
3-20 (0.100 g, 0.063 mmol) of mono dimethylpropyl 4-(5-bromo-2-
thienyl)benzenesulfonate cavitand was placed into a sealable reaction vessel.  5-
(5-bromo-2-thienyl)-2-butylpyridine (0.056 g, 0.189 mmol) was placed into a vial 
and both containers were brought into the glove box. 1.00 mL of dry THF was 
added to the thiophene and the solution was chilled to -78° C.  Then, (0.120 mL, 
0.200 mmol) 1.6 M n-butyl lithium in hexanes was added rapidly.  After 5 
minutes, (0.068 g, 0.504 mmol) zinc chloride was dissolved in 1.00 mL of dry 
THF was transferred to the thiophene solution.  The zinc species and (0.007 g 
.006mmol) tetrakis(triphenylphosphine)palladium(0) was added to the sealable 
reaction vessel.  The reaction vessel was taken out of the glove box and heated 
to 70°C for 8 hours.  The reaction was allowed to reach room temperature and 
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15.0 mL of methylene chloride was added to quench the reaction.  The 
methylene chloride was washed with 15.0 mL of brine.  The layers were 
separated and the organic layer was dried with magnesium sulfate, filtered and 
concentrated.  The crude product was isolated via column chromatography with a 
gradient from 99:1 hexane:ethyl acetate to 75:25 hexane:ethyl acetate to 
produce A,B sulfonate,pyridine cavitand 3-21 as an oily residue (0.070 g, 67% 
yield).  1H NMR (400 MHz, CDCl3)   δ 0.85 - 0.98 (m, 25 H) 1.21 - 1.49 (m, 72 
H) 1.67 - 1.75 (m, 2 H) 2.22 - 2.33 (m, 8 H) 2.79 (t, J=7.42 Hz, 2 H) 3.69 (s, 2 H) 
4.37 (d, J=7.03 Hz, 1 H) 4.40 - 4.49 (m, J=7.03, 7.03 Hz, 3 H) 4.73 - 4.93 (m, 
J=8.20, 8.20 Hz, 4 H) 5.68 - 5.81 (m, J=7.03, 7.03, 7.03 Hz, 4 H) 6.51 (s, 1 H) 
6.51 (s, 1 H) 7.16 (d, J=7.81 Hz, 1 H) 7.18 - 7.22 (m, J=4.29, 4.29 Hz, 5 H) 7.24 
(d, J=3.90 Hz, 1 H) 7.40 (d, J=3.90 Hz, 1 H) 7.72 (d, J=8.59 Hz, 2 H) 7.74 - 7.77 
(m, J=2.34 Hz, 1 H) 7.88 (d, J=8.59 Hz, 2 H) 8.73 (d, J=1.95 Hz, 1 H); 13C NMR 
(101 MHz, CDCl3)   δ 14.1, 14.3, 22.6, 22.7, 22.9, 26.2, 28.1, 29.6, 29.7 - 30.2, 
30.4, 30.7, 31.9, 32.2, 36.6, 36.9, 37.3, 38.0, 38.0, 79.9, 99.8, 100.1, 100.2, 
116.5, 116.6, 120.5, 120.7, 120.9, 121.6, 121.9, 122.9, 123.7, 124.6, 125.0, 
125.3, 126.0, 127.5, 128.9, 130.1, 130.4, 133.2, 133.6, 134.4, 135.6, 137.2, 
138.3, 138.4, 138.6, 138.8, 138.9, 139.0, 139.4, 139.9, 141.1, 142.1, 146.3, 
146.4, 152.5, 152.6, 152.7, 155.0, 155.1, 155.2, 161.9  
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A,B-Mono-thiophene-dimethylpropylbenzenesulfonate-mono-
thiophene-pyridinium-triflate-bishydrogen resorcin[4]arene[3-22] 
 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
H
H
S
SO O
O
S
N
Bu
O
S
O
O
F3C
 
compound 3- 22 
 
(0.071 g 0.023 mmol) A,B sulfonate,pyridine cavitand, 3-21 (0.014 g, 0.116 
mmol) methyl triflate, and 1.00 mL of dry chloroform was transferred to a 
sealable reaction container.  The reaction was allowed to stir overnight at room 
temperature.  The solvent and excess methyl triflate was removed via high 
vacuum.  The remaining residue was extracted with 5.00 mL of hexane, which 
was decanted off to yield A,B sulfonate, methyl pyridinum cavitand as the desired 
product as an oily light brown residue.  By NMR the reaction showed 100% 
conversion from starting materials to products. Purification by column 
chromatography 95:5 chloroform : methanol produced 0.030 g (37% yield) of the 
title compound 3-22.1H NMR (400 MHz, CDCl3)   δ 0.98 (t, J=7.42 Hz, 4 H) 1.18 
- 1.53 (m, 50 H) 1.68 - 1.79 (m, J=8.20 Hz, 2 H) 2.12 - 2.48 (m, 8 H) 2.95 - 3.02 
(m, J=7.81 Hz, 2 H) 3.67 (s, 2 H) 4.34 (d, J=7.42 Hz, 1 H) 4.43 - 4.51 (m, J=7.03 
Hz, 3 H) 4.74 - 4.92 (m, J=7.81, 7.81, 7.81 Hz, 4 H) 5.67 (d, J=7.42 Hz, 1 H) 5.72 
- 5.81 (m, J=7.42, 7.42, 7.42 Hz, 3 H) 6.50 (s, 1 H) 6.56 (s, 1 H) 7.15 - 7.24 (m, 5 
H) 7.40 (d, J=3.51 Hz, 1 H) 7.66 (d, J=4.29 Hz, 1 H) 7.71 (d, J=8.59 Hz, 2 H) 
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7.85 (d, J=8.20 Hz, 2 H) 8.33 (d, J=7.81 Hz, 1 H) 9.23 (s, 1 H); 13C NMR (101 
MHz, CDCl3)   δ 13.6, 14.1, 22.3, 22.7, 26.0, 27.9, 28.0, 29.3, 29.4, 29.6 - 30.0, 
30.0 - 30.3, 30.4, 31.6, 31.9, 32.3, 36.4, 36.7 - 36.8 (m, J=4.42 Hz, 2) 37.1, 45.9 , 
79.8, 99.6, 99.8, 99.9, 100.4, 116.6, 120.4, 120.5, 120.8, 121.0, 121.6, 125.3, 
125.8, 127.9, 128.5, 130.3, 130.8, 133.0, 133.9, 134.7, 135.4, 137.7, 137.9, 
138.0, 138.3, 138.5, 138.6, 138.9, 139.3, 140.2, 141.8, 142.9, 152.3, 152.4, 
152.6, 154.7, 154.9, 155.1, 155.8 
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A,B-Mono-thiophene-benzenesulfonate-mono-thiophene-
pyridinium-triflate-bishydrogen resocin[4]arene[3-22]6 
 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
H
H
S
SO O
O
S
N
Bu
 
Compound 3-22  
     
 
The A,B sulfonate, methyl pyridinum cavitand 3-21 (0.085 g, 0.046 mmol), (.015 
g 0.138 mmol) tetramethylammonium chloride and 1.00 mL DMF was transferred 
to a sealable reaction container.   The flask was evacuated then purged with 
nitrogen.  The reaction was heated for 24 hours at 150°C.  After cooling to room 
temperature, the reaction solution was evaporated to dryness via high vacuum.  
15.0 mL of methylene chloride was added and washed with saturated brine 
solution.  The organic layer was dried with magnesium sulfate, filtered and 
concentrated.  The crude product was purified via column chromatography with a 
gradient from 100% chloroform to 85:15 chloroform:methanol yielding the 
deprotected A,B sulfonate, methyl pyridinum cavitand as an oily residue of  the 
title compound 3-22 (0.040 g, 52% yield) .1H NMR (400 MHz, CDCl3)   δ 0.86 - 
0.93 (m, 15 H) 1.24 - 1.48 (m, 72 H) 1.64 - 1.74 (m, 2 H) 2.29 (s, 8 H) 2.78 (t, 
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J=7.42 Hz, 2 H) 4.36 (d, J=7.03 Hz, 1 H) 4.46 (d, J=7.03 Hz, 3 H) 4.72 - 4.92 (m, 
J=7.81 Hz, 4 H) 5.69 - 5.80 (m, 4 H) 6.50 (s, 1 H) 6.50 (s, 1 H) 7.12 - 7.20 (m, 4 
H) 7.21 - 7.29 (m, 6 H) 7.34 - 7.43 (m, 1 H) 7.54 (d, J=7.81 Hz, 2 H) 7.75 (d, 
J=9.37 Hz, 1 H) 7.94 (d, J=7.81 Hz, 2 H) 8.73 (s, 1 H); 13C NMR (101 MHz, 
DMSO-d6)   δ 13.7 - 13.7, 13.7 - 13.9, 21.6 - 21.8, 21.9 - 22.2,  27.5 - 27.8,  28.7 
- 28.8, 29.1, 29.3, 29.6, 31.2, 31.3, 36.2, 36.7, 36.8 - 37.3, 98.9, 99.3, 99.6, 
116.2, 121.4, 121, 121.5, 121.7, 122.3, 122.6, 123.4, 123.8, 124.5, 126.2,  126.9, 
130.0, 132.8, 132.9, 133.1, 133.6, 137.9, 138.0, 138.4, 140.2, 143.2, 145.2, 
146.9, 151.6, 151.7, 154.1, 160.6 
 
2-butyl-5-(2-thienyl)pyridine [3-23] 
S N
 
compound 3- 23 
 
3-1 (0.400 g, 2.48 mmol) and 6.00 mL of dry THF was placed in a schlenck flask.  
The vessel was chilled to -78oC and (0.400 g, 6.2 mmol, 3.9 mL) n-butyl lithium 
was added to the reaction vessel.  The solution was allowed to warm to 0oC then 
to room temperature and then monitoring by TLC for disappearance of starting 
material 4:1 hexane:ethyl acetate.  5.00 mL of H2O was added to the reaction 
vessel and the solution was extracted with DCM.  The organic layer was dried 
with magnesium sulfate, filtered and concentrated.  The crude was purified via 
column chromatography with 4:1 hexane:ethyl acetate to get 0.230 g (1.0 mmol, 
43% yield) of the title compound 3-23.1H NMR (400 MHz, CDCl3) d δ 0.953 (t, 
J=7.42 Hz, 3 H) 1.35 - 1.46 (m, J=15.23, 7.42 Hz, 2 H) 1.68 - 1.79 (m, J=7.42 Hz, 
2 H) 2.81 (t, J=7.81 Hz, 2 H) 7.11 (dd, J=3.90 Hz, 1 H) 7.157 (d, J=8.20 Hz, 1 H) 
7.30 - 7.34 (m, 2 H) 7.31 - 7.33 (m, J=2.73 Hz, 1 H) 7.33 - 7.33 (m, J=1.17 Hz, 1 
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H) 7.77 (dd, J=8.00, 2.54 Hz, 1 H) 8.78 (d, J=2.34 Hz, 1 H); 13C NMR (101 MHz, 
CDCl3) d δ 13.9, 22.5, 32.0, 37.8, 122.6, 123.6, 125.4, 127.7, 128.1, 133.5, 
140.8, 146.4, 161.5 
 
5-(5-bromo-2-thienyl)-2-butylpyridine [3-24]5 
 
S
Br N
 
compound 3- 24 
The reaction vessel was wrapped in foil to prevent exposure to light.  2-butyl-5-
(2-thienyl)pyridine [3-23] (0.200 g, 0.920 mmol) was dissolved in DCM (4.00 mL). 
A solution of bromine (0.191 g, 0.060 mL, 1.2 mmol) in DCM (1.40 mL) was 
added dropwise over 30 min. The reaction was stirred at ambient temperature for 
2 hrs. A 1.00 M aqueous solution of sodium carbonate (5.00 mL) was added and 
the mixture was stirred. The layers were separated and the aqueous phase was 
extracted with additional dichloromethane (15.0 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated to give 0.200 g (76% 
yield) of the title compound 3-24. 1H NMR (400 MHz, CDCl3)   δ 0.88 - 1.03 (m, 
J=7.42 Hz, 3 H) 1.32 - 1.49 (m, J=7.42 Hz, 2 H) 1.63 - 1.80 (m, J=7.42 Hz, 2 H) 
2.82 (t, J=7.81 Hz, 2 H) 7.06 (s, 2 H) 7.18 (d, J=8.20 Hz, 1 H) 7.71 (d, J=8.20 Hz, 
1 H) 8.70 (s, 1 H); 13C NMR (101 MHz, CDCl3)   δ 14.1, 22.6,  32.1, 37.9, 122.7, 
123.8, 125.5, 127.8, 128.3, 133.6, 140.9, 146.5, 161.7 
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Chapter 4 Dimeric Capsule by Electrostatic 
interactions 
 
.4.1,1-Introduction 
 
Molecular capsules have been studied extensively for their ability to 
encapsulate molecular species and lower activation barriers in kinetically 
unfavorable reactions1-3.  Many have used molecular capsules in aqueous 
environments as a model for enzymes and proteins4.  Non-covalent forces are 
commonly utilized to yield cooperative systems for the encapsulation of guests5.  
It is known that tight ion pairs that exist in both non-polar and polar media can 
disrupt electrostatic interactions. 
 In this project, the synthesis of a dimeric electrostatic capsule and the 
quantification of the underlying forces for dimerization are presented.  In 
comparing binding enthalpies (ΔH°) to analogous binding enthalpies of non-
capsule forming model salt bridges, we are able to elucidate cooperatively due to 
quadrupolar change alignment.  In figure 4.1, the two most energetically favored 
alignments are shown below.  In alignment 1 the salt bridge is parallel where the 
electrostatic interaction is linear.   
 
Figure 4.1 shows parallel and anti-parallel configurations for the dimeric capsule. 
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Alignment 1                             Alignment 2 
Figure 4.2 Most favorable alignment for the dimeric capsule. 
 
In alignment 2 the salt bridge is antiparallel while the two 
resorcin[4]arenes are interdigitating between each other.  In contrast, alignment 1 
constitutes two parallel dipoles.  It was expected that the quadrupole would yield 
tight ion pairs that are lower in energy than two separate dipoles.  To 
demonstrate that our capsules have a quadrupolar arrangement, the association 
constants are compared to those of single dipoles. 
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4.1,2-Synthesis of half-capsules 
 
The capsule is based on two hemi-capsules with an A,C distribution on the 
upper rim as described in chapter 2.  This A,C  pattern is generated from the 
lithiation of the tetrabromo cavitand followed by tri-isopropyl borate.  The 
Sherburn group has established precedence for the formation of the A,C pattern 
due to the charge repulsion of two lithium species on the upper rim.6 
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Scheme 4.1 synthesis of the A,C bis-pyridinium salt  a)Pd(PPh3)4, 2 M Na2CO3, THF 55 % 
yield  b) Methyl iodide, THF 85% yield. 
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Suzuki couplings were employed to decorate the upper rim of the 
resorcin[4]arene (Figure 4.3).  The use of a 3-(5-bromo-2-thienyl)pyridine  3-2 
and 2,2-dimethylpropyl 4-(5-bromo-2-thienyl)benzenesulfonate 3-5 was utilized 
as a linker to position the charged species for a cooperative geometry to 
synthesize a dimeric capsule.  This five-membered ring provided a curvature to 
direct the functional groups on the upper rim to orientate them in a 
positive/negative/positive/negative quadrupolar pattern. 
 
Both hemicapsules 4-11 and 4-13 were synthesized as neutral 
components that contained functional groups capable of generating a charged 
species. The pyridine resorcin[4]arene 4-10 was treated with methyl iodide to 
generate 4-11.  The use of 2,2-dimethylpropyl 4-(5-bromo-2-
thienyl)benzenesulfonate 4-5  was employed to generate an anionic species 
through the removal of the 2,2-dimethylpropyl group using tetramethyl 
ammonium chloride in DMF.  Compound 4-13 was purified via reverse phase 
column chromatography in THF.   In a 1:1 ratio, the two cavitands 4-11 and 4-13 
were each dissolved in DMSO and mixed together to generate a dimeric 
insoluble capsule. 
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Scheme 4.2 Synthesis of the A,C bis sulfonate tetramethyl ammonium salt. 
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Figure 4.3  A,C bis-pyridinium and A,C bis-sulfonate half capsules. 
 
The H1 NMR spectrum shows a 1:1 ratio of 1 and 2 and displays both 
pyridinium and sulfonate moieties relative to their precursors.  The pyridinium 
signals at 9.65, 9.00, 8.57 and 8.06 became broad signals at 9.40, 8.90, 8.10 and 
7.98.  Noticeable shifts were also observed in the sulfonate.  Sharp doublets at 
7.84 and 7.58 yielded broad singlets at 7.84 and 7.57.  Changes were also 
observed for the methyl group from the pyridinium with an upfield shift of 0.11 δ 
relative to 1. Figure 4.7 shows 1H NMR spectrum of the 4-11, 4-13 and 4-14.  
The bottom spectrum of C shows the 1H of the 4-11.  The middle spectrum B 
shows 4-13 and the A is the dimeric capsule 4-14.  The box  represents the 
pyridinium peaks, the circle  represents the sulfonate peaks present and the 
star * represents the outer bridges from the resorcin[4]arene.  The x represents 
the methyl group from the pyridinium.  The stacked spectrum (figure 4.7) shows 
the sulfonate 4-13 and pyridinium 4-11 hemicapsules are present in the dimeric 
capsule 4-14.  
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Figure 4.4 H1 NMR in CDCl3 a) capsule b)sulfonate hemicapsule c) pyridinium hemicapsule. 
 
The use of 2D NOESY in CDCl3 was employed to confirm the contact 
between the sulfonate and pyridinium species.  The NOESY spectrum shown 
below yields a cross peak between the sulfonate at 7.81 ppm and the methyl 
group of the pyridinium cavitand. The methyl group was used as probe to 
determine the proximity of hemicapsule 1 to hemicapsule 2 in the dimeric 
species.    
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Figure 4.5 2-D NOESY of dimeric capsule in CDCl3;   = sulfonate,   = methyl from 
pyridinium. 
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Figure 4.6  Dimeric capsule of bis sulfonate and bis pyridinium cavitand 1-2 complex  R= 
C11H23.. 
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4.2,1-Model Studies 
 
A reference salt was synthesized to compare the energies of electrostatic 
attractions of capsule to a ‘non-capsule’ analog.   
SN
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Figure 4.7  Complex 4-7 thiophene-based model salt. 
 
A decoupling experiment was performed to confirm contact between 
sulfonate and pyridinium.  The decoupling experiment was executed in a polar 
media such as dimethylsulfoxide and a non-polar media such as chloroform.  It is 
known that ion pairs are solvent dependent and polar solvents such as water and 
dimethyl sulfoxide, dimethylformamide would disrupt ion pairs.  The objective 
was to understand which solvent would provide the tightest ion pair contact.  The 
use of 1H NMR spectroscopy was employed to determine a suitable solvent for a 
tight ion pair between the sulfonate and the pyridinium.  In the decoupling 
experiment a signal enhancement determines the proximity of one C-H bond to 
another C-H bond.  Here, the focus is to determine the proximity of the sulfonate 
to the pyridinium in polar and non-polar solvents.  As shown in the Figure 4.11, 
the α-methylene of pyridinium was utilized as a probe to determine the proximity 
of the sulfonate to the pyridinium.  The α-methylene of pyridinium at 4.89 ppm 
was irradiated and signals from 9.48 ppm and 8.93 ppm were affected.  The 
signal at 9.48 ppm and 8.93 ppm are representative of the pyridinium.   The 
sulfonate doublet at 7.84 ppm showed a positive NOE, which demonstrates the 
sulfonate is within 5.00 Å from the pyridinium.  The same decoupling experiment 
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was performed in dimethylsulfoxide and the same α-methylene of pyridinium was 
irradiated.  This yielded an irradiated signal from 9.49 ppm and 8.93 ppm from 
pyridinium.  The sulfonate doublets did not show enhancement in 
dimethylsulfoxide-d6.  This study demonstrates that tight ion pairs of 1 and 2 are 
formed in chloroform-d, but not dimethylsulfoxide-d6.   
 
 
Figure 4.8:decoupling experiment of 4-7 in chloroform-d. 
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Figure 4.9 is a decoupling experiment of 4-7  in dimethylsulfoxide-d6. 
 
4.3-Dilution Studies by NMR 
 
Dilution studies were employed to determine binding constants to 
ultimately compare energies of the model salt thiophene and the dimeric capsule.  
The use of 1H NMR spectroscopy allowed for measurements of chemical shifts in 
the range of 40.0 mM and 0.006 mM, assuming a 2-state model that favors ion-
pairs at high concentrations.   With complexation-induced NMR shifts, one can 
determine the Kdiass by establishing an aggregated and disaggregated state.  In 
this system, the complex 4-7 and 4-14 is concentration dependent and dilution 
can be employed to disaggregate the complex.  Studies were performed in 
chloroform to yield adequate electrostatic interactions between the sulfonate and 
pyridinium. It has been established in other systems that complexation can be 
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observed by NMR-monitoring of the changes in chemical shifts of pyridinium and 
sulfonate; therefore, dilution of our salts would provide a quantitative method for 
determining the strength of the sulfonate and pyridinium ion pairs.   
Measurements were executed in chloroform to provide insight for the 
binding constant of the sulfonate-pyridinium complex in chloroform.  Studies were 
performed to determine the equilibrium between the ABass and ABdiss based on 
the apparent NMR shifts with dilution studies.  For a 1:1 complex with an 
disassociation constant, Kdiass, is kept constant but dilution lowers the ratio of 
sulfonate-pyridinium complex compared to the sulfonate half-capsule and the 
pyridinium half-capsule.  This way we disrupt the salt bridges via dilution even 
though ΔG°diass is favorable for binding. 
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Equation 4.1 shows the calculation for equilibrium constant for the dilution studies 
 
Dilution studies were performed in concentrations from 38.0 mM (100% 
aggregation) to 0.019 mM (100% deaggregation).  Data points that showed 
chemical shifts between the plateaus for 100% aggregation and 100% 
deaggregation were analyzed according to equation below.   
total
dissoc
aggregated
S
SS
x
!
=
 
Equation 4.2 shows the calucation for the plateaus in the dilution studies 
 
Upon dilution by a factor of two, chemical shifts changes up to 0.200 δ were 
observed. The NMR studies lead to Kass value of 9.2 M-1 and ΔG°ass energy of 1.3 
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kcal/mol.  This provides insight for the binding energy of a single dipole attraction 
between a sulfonate and pyridinium in chloroform.  This was used as a model 
compound for the sulfonate-pyridinium complex in our dimeric capsule. 
 
 
Figure 4.10  Dilution curve for 4-7 thiophene model salt. 
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Figure 4.12a Expansion of the dilution curve for 4-7 thiophene model salt which identifies 
the deaggreated plateau.  
 
 
Figure 4.11  Dilution study for the A,C bis-pyridinium iodide 4-11. 
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Figure 4.13a shows the expansion of the dilution study which identifies the deaggregated 
plateau.  
 
1H NMR studies were also employed with the pyridinium iodide 4-11 as a 
reference compound to determine the affinity of the iodide to the pyridinium.  
Dilution studies were executed in chloroform to determine a Kdisass of  -50.3 M-1 
and - 2.3 kcal /mol.   Our measurements were based on establishment of the fully 
aggregated state with 14.4 mM and fully disaggregated at 0.056 mM.  The 
disaggregated state was based on the reproducible chemical shifts at low 
concentrations of substrate.  Similarly, the aggregated state was based on the 
small changes in chemical shift with high concentrations.   
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Figure 4.12  Dilution study of the A,C bis pyridinium iodide cavitand. 
 
Similar studies were employed on the 4-14 capsule to calculate the Kdiass 
in chloroform.  Based on dilution studies, Kdisass constant of -96.0 M-1 and ΔG°ass 
of -2.70 kcal/mol were calculated.  From the dilution curve it is apparent that in 
the concentration domain of 3.00 to 6.00 mM, only the dimeric species 4-14 
exists while in the domain of 0.012 and 0.006 mM disaggregation is observed 
(Figure 4-16).     
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Figure 4.13  Dilution curve for the 4-14 dimeric capsule. 
 
 
Figure 4.15a shows expansion of dilution curve, which demonstrates the deaggregated 
plateau. 
The comparison of the Kdisass constants of 4-14 complex and 4-7 complex 
provides insight for the strength of the electrostatic interactions between the 
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dimeric species and the single dipole.  We anticipated the dimeric capsule to 
yield ΔG°ass values higher than our experimental values.   A ΔGo of -2.70 
Kcal/mol for dimeric capsule does not suggest a quadrupolar alignment is not the 
most thermodynamically preferred for the 4-14 complex, based on the 
comparison of ΔGo values.  It is possible the 4-7 complex can align in a more 
cooperative fashion than the 4-14 capsule, due to fewer alignment constraints.  
The difference of 1.40 kcal/mol implies that two dipole-dipole interactions are 
present in the dimeric capsule. Dilution studies yielded measurable changes in 
chemical shift (figure 4.17).  The methyl group at 4.63 ppm changes to 4.73 ppm 
due to the dilution in chloroform-d.  Sharpening of signals was also observed as 
the concentration of 4-14 was decreased.   
 
Figure 4.14  Dilution study of  4-14 dimer capsule in chloroform 
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Compound Kdisass ΔGodisass 
 
4-14 
-96 M-1 -2.7 kcal/mol 
 
4-7 
-9.2 M-1 -1.3 kcal/mol 
 
4-11 
-50.3 M-1 -2.3 Kcal/Mol 
Table 4-1 Disassociation constants and ΔG values. 
 
These findings are consistent with the data of Schneider et al who found 
5.00 + 1.00 kJ/Mol per salt bridge in sulfonate pyridinium  ion-pair complex in 
water.7  These studies seem to favor the notion that the dimeric capsule is held 
together by two independent salt bridges (alignment 1 in Figure 4.2). 
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4.4-Competitive Binding Study: 
 
Salt brides between sulfonates and pyridiniums hold these capsules 
together.  Initially, the plan was to use 1,4-dimethyl pyridinium iodide as a guest 
molecule to bind inside the inner cavity of the capsule.  After performing a 
titration experiment with 76-fold excess of the 1,4-dimethyl pyridinium a new 
stable species formed.  The main question was whether there was 2:1 binding or 
1:1 binding in the system.   
 
Figure 4.15 Competitve Binding Study. 
 
A Job Plot (Figure 4.19) established 2:1 binding (maximum at 0.3) rather 
than 1:1 binding, consistent with capsule disruption rather than with 
encapsulation. 
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Figure 4.16  Job plot of the bis-sulfonate dimethyl pyridinium salt 
 
 
Figure 4.17  Disruption of the dimeric capsule with dimethyl pyridinium iodide 
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Determination of Kbind was possible via the Bernesi-Hildebrand approach 
(Figure 4.21). The 1H NMR signals show averages of the free sulfonate cavitand 
and the sulfonate dimethyl pyridinium cavitand.  From plotting the inverse of the 
guest concentration 1/[G]o versus the inverse of the mole fraction slope, the Ka 
equilibrium constant can be calculated using the equation below.   
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Equation 4.3 is used to determine Kbind via Bernesi-Hildebrand 
 
A Ka of 3.8 M-1 was calculated from the slope which is similar to the value 
determined by dilution studies with the pure dimethyl pyridinium bis sulfonate salt 
4-16.  
 
Figure 4.18  Bernesi-Hilderbrand Plot 
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4.5-Host:Guest Studies 
 
A series of guest molecules were surveyed to gain insight on the size and 
shape of the cavity.  Initially, efforts were focused on binding aromatic molecules 
such as toluene, benzene, 1,4 dimethoxy benzene, 1,4 dicyanobenzene and 1,4 
diiodobenzene.  Unfortunately, none of these aromatic substrates would bind to 
the inner cavity.  Cram established small molecules such as acetonitrile and 
carbon disulfide to bind to the inner cavity of some his capsules and hemi-
carcerands8.  The major challenge with uncovering a guest molecule is that it 
must have good size and shape matches, but it should not disrupt the 
electrostatic interactions between the sulfonate and pyridinium; therefore, 
molecules with large dielectric constants were avoided in other studies because 
they may disrupt the electrostatic interactions.  
 
 
Figure 4.19  Titration of acetonitrile guest of compound 4-14 in ghloroform-d 
118 
 
As shown in the figure 4.27 above, as the concentration of acetonitrile is 
increase an upfield shift occurs but at high concentrations a drastic shift occurs.  
Also, the peaks begin to sharpen and doublets are resolved for the bridges.  
Therefore, acetonitrile is a poor candidate for host: guest studies.   
 
 
Figure 4.20  Titration of carbon-disulfide guest of compound 4-14 in chloroform-d. 
 
The use of carbon disulfide was employed which has no net dipole 
moment.  After an 800 fold excess 200uL complete 1:1 binding was observed by 
NMR.  As shown in the diagram below the bridges and methyl group from the 
pyridinium changed upon binding.   In some cases the pyridinium peaks shifted 
as much as 0.120 ppm.   
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Figure 4.21  Host-guest study with carbon disulfide. 
 
To establish that binding occurred in the capsule binding studies were 
performed with the sulfonate half-capsule and pyridinium half-capsule.  No 
changes were observed in the 1H NMR spectra even at high concentration of CS2 
support the notion that half-capsules are unsuitable for CS2 binding.      
 
 
Figure 4.22  Host-guest study with A,C bis sulfonate and A,C bis pyridinium hemicapsules. 
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4.6-Van’t Hoff Studies  
 
Complexation between the sulfonate and pyridinium half capsules may be 
driven by entropy and/or enthalpy; therefore, ΔH° and ΔS° had to be determined.  
A series of 1H NMR spectra of 1-2 were acquired over a temperature range of 
60°C (-10°C to 50°C) and the amount of 1,2 and 1-2 was determined at each 
temperature.   
 
Figure 4.23  Variable temperature studies for dimeric capsules. 
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To calculate the ΔH° and ΔS° dilution studies were performed to map out 
extreme plateaus for aggregated and disaggregated states for the capsule and 
bis-dimethyl bis-sulfonate cavitand.  The concentration was kept constant in a 
range in which the equilibrium is not between the two components of the capsule. 
An increase in temperature results in the deconvolution of the bridges from the 
two hemicapsules 4-11 and 4-13.   
 
Figure 4.24  Variable temperature studies of bis-sulfonate dimethyl pyridinium salt. 
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By varying the temperature, a total change in chemical shift of 0.100 ppm 
for the capsule and 0.030 ppm for the bis-dimethyl pyridinium bis-sulfonate 
cavitand was observed.   
 
Figure 4.25  Van’t Hoff plot for bis-sulfonate dimethyl pyridinium. 
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Figure 4.26 Van't Hoff plot for dimeric capsule. 
 
From Van’t Hoff plots, ΔH° and ΔS° were determined according to: 
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Equation 4.4 is used for the Van't Hoff experiment to calculate enthalpy and entropy 
 
As shown in Table 4.2, the capsule ΔHo and ΔSo is -1.90 kcal/mol-1 and 1.80 kcal 
mol-1 K-1, respectively and the ΔG° is -0.45 kcal/mol-1 and 3.60 kcal/mol-1.  This 
underlined that capsule formation in CDCl3 is both enthalpy and entropy driven, 
while the reference compound forms ion pairs demonstrate this is an entropy 
driven process. The capsule is slightly enthalpy driven and the 4-16 bis-
dimethylpyridinium bis-sulfonate is more entropy driven.  Since the capsule is a 
more enthalpy driven process, this suggests that solvent-to-surface attractions 
are present in our system.  These attractions are driving forces that are dominant 
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in the formation of the capsule.  These enthalpy driven forces are present in 
Crams Velcraplexes, which are also driven by ‘solvophobic’ binding driving 
forces.9 
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Table 4-1 shows the ethalpy, entropy, and ΔG disassociation values determined for 4-14 
and 4-16 
Compound Enthalpy 
(ΔHodissoc) 
Entropy(ΔSo) 
Gibbs 
(ΔGoassoc) 
 
4-14 
-1.88 kcal/mol-1 
1.8 kcal mol-1 K-
1 
2.7 
kcal/mol-1 
 
4-16 
-0.45 kcal/mol-1 3.6 kcal/mol-1 
1.6 
kcal/mol-1 
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4.7 Conclusions and Outlook 
 
 The use of dilution studies through 1H NMR was utilized to determine ΔH, 
ΔS, and ΔG for the dimeric capsule 4-14, bis-sulfonate-dimethylpyridinium iodidie 
4-16 and thiophene model salt 4-7.  Van't Hoff studies were implemented to 
compare the ΔH values to compare the capsule to a system that can align itself 
as two dipoles.  The ΔH value for the capsule 4-14 is -1.88 kcal/mol and the -0.45 
kcal/mol for 4-17.   This suggests something is special about the alignment of the 
dimeric capsule 4-14 relative to the 4-17. 
4.8 Future Studies  
 
The use of 3-bromopyridine was employed as starting building block for 
the synthesis of the pyridinium half-capsule.  Also, 4-bromo-sulfonyl chloride was 
utilized as the starting building block for the synthesis of the sulfonate cavitand.  
The use of two para functionalized pyridinium and sulfonate aromatics could 
generate a more cooperative binding system.  Studying the effect of different 
para versus meta substituted pyridinium and sulfonate aromatics could lead to 
different disassociation constants.  
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Chapter 5 4.9-Experimental 
3-(2-thienyl)pyridine [4-1]  
 
S N
 
 
Compound 4 - 1 
 
To a reaction vessel, 3- bromo-pyridine (1.01g, 6.42 mmol, 0.619 mL), 2-
thiophene boronic acid (0.685 g, 5.35 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.310 g, 0.268 mmol), 2.00 M sodium 
bicarbonate (6.00 mL) and toluene (13.0 mL) were added.  The reaction vessel 
was degassed by freeze-pump-thaw.  The reaction was heated at 80o C for 10 
hours. The reaction was quenched by the addition of a saturated sodium 
bicarbonate solution.  Methylene chloride was added and the aqueous and 
organic layers were separated.  The organic layer was dried with magnesium 
sulfate, filtered and concentrated.  The product was isolated by column 
chromatography with 3:1 hexane:ethyl acetate to yield a light brown oil 3-(2-
thienyl)pyridine to give (1.00 g, 80% yield) as the title compound 4-1. 10 1H  NMR 
(400 MHz, CDCl3)   δ 7.12 (dd, J=4.29 Hz, 1 H) 7.30 (dd, J=7.22, 4.88 Hz, 1 H) 
7.36 (d, J=3.90 Hz, 2 H) 7.86 (d, J=8.20 Hz, 1 H) 8.51 (d, J=4.69 Hz, 1 H) 8.89 
(d, J=1.95 Hz, 1 H) 13C NMR (101 MHz, CDCl3)   δ 123.6, 124.2, 125.9, 128.2, 
130.3, 132.9, 140.4, 146.9, 148.4  
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3-(5-bromo-2-thienyl)pyridine [4-2]  
 
S NBr
 
Compound 4 - 2 
 
The reaction vessel was wrapped in foil to prevent exposure to light. Compound 
3-(2-thienyl)pyridine 4-1 (4.36 g, 27.1 mmol) was dissolved in DCM (91.0 mL). A 
solution of bromine (1.81 mL, 35.0 mmol) in dichloromethane (45.0 mL) was 
added drop wise over 30 min. The reaction was stirred at ambient temperature 
for 2 hrs. A 1.00 M aqueous solution of sodium carbonate (30.0 mL) was added, 
and the mixture was stirred. The layers were separated and the aqueous phase 
was extracted with additional dichloromethane (30.0 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated to give 5.87 g (90% 
yield) of 3-(5-bromo-2-thienyl)pyridine of the title compound 4-2.10 1H NMR (400 
MHz, CHLOROFORM-d) d ppm 7.057 (d, J=3.55 Hz, 1 H) 7.079 - 7.112 (m, 
J=3.81 Hz, 1 H) 7.292 (dd, J=7.86, 7.48, 5.20, 4.06 Hz, 1 H) 7.712 - 7.784 (m, 
J=2.28 Hz, 1 H) 8.525 (dd, J=4.82, 1.52 Hz, 1 H) 8.783 (d, J=1.78 Hz, 1 H).  13C 
NMR (50 MHz, CDCl3)   δ 112.7, 123.6, 124.4, 129.5, 131.0, 132.6, 141.7, 
146.5, 148.7  
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2,2-dimethylpropyl 4-bromobenzenesulfonate [4-3]11 
S
O O
O
Br  
Compound 4 - 3 
 
4-bromo-sulfonyl chloride (0.66 g, 2.60 mmol), neopentyl alcohol (0.23 g, 2.6 
mmol) and 26 mmol (2.00 mL) of pyridine were added to a round-bottom flask.  
The pyridine was removed in vacuo and the remaining contents were dissolved 
in 10.0 mL of diethyl ether.  The ether was washed with 2.50 M HCl (15.0 mL).  
The organic and aqueous layers were separated and the organic layer was 
washed again with 2.50 M HCl.  The organic layer was separated, dried with 
magnesium sulfate, filtered and concentrated.  The crude was dissolved in 
diethyl ether and layered with hexane to induce precipitation on the needle-like 
crystals of 2,2-dimethylpropyl 4-bromobenzenesulfonate to give (0.662 g 83% 
yield) of the title compound 4-3.  1H NMR (400 MHz, CDCl3)   δ 0.880 - 0.940 
(m, 9 H) 3.70 (s, 2 H) 7.69 - 7.73 (m, J=8.20 Hz, 2 H) 7.75 - 7.80 (m, J=8.20 Hz, 
2 H); 13C NMR (101 MHz, CDCl3)   δ 26.2, 31.9, 80.1, 129.0, 129.5, 132.7, 
135.3  
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2,2-dimethylpropyl 4-(2-thienyl)benzenesulfonate [4-4]10 
SO O
O
S
 
 
Compound 4 - 4 
 
To a sealable reaction vessel, 4-3 2,2-dimethylpropyl 4-bromobenzenesulfonate 
(0.580 g 1.89 mmol), 2-thiophene boronic acid (0.220 g, 1.72 mmoles), 
tetrakis(triphenylphosphine)palladium(0) (0.080 g, 0.070 mmol), 2 M sodium 
bicarbonate (2.10 mL) and toluene (4.00 mL) were added.  The reaction vessel 
was degassed by freeze-pump-thaw.  The reaction was heated for 10 hours at 
70oC. The reaction was quenched by the addition of a saturated sodium 
bicarbonate solution. The aqueous layer was extracted with methyl chloride and 
the layers were separated.  The organic layer was dried with magnesium sulfate, 
filtered and concentrated.  The product was isolated by column chromatography 
with 4:1 hexane:ethyl acetate to yield 2,2-dimethylpropyl 4-(2-
thienyl)benzenesulfonate a white solid to give (0.310 g, 57% yield) as the title 
compound 4-4.10 1H NMR (400 MHz, CDCl3)   δ 0.910 (s, 9 H) 3.70 (s, 2 H) 7.14 
(dd, J=3.90 Hz, 1 H) 7.41 (dd, J=5.08, 1.17 Hz, 1 H) 7.45 (dd, J=3.90, 1.17 Hz, 1 
H) 7.76 (d, J=8.59 Hz, 2 H) 7.89 (d, J=8.20 Hz, 2 H);13C NMR (101 MHz, CDCl3) 
  δ 26.2, 31.9, 79.9, 125.5, 126.3, 127.3, 128.7, 128.8, 134.4, 139.7, 142.1  
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Dimethylpropyl 4-(5-bromo-2-thienyl)benzenesulfonate[4-5] 
SO O
O
S
 
 
Compound 4 - 5 
 
The reaction vessel was wrapped in foil to prevent exposure to light. Compound 
4-4 2,2-dimethylpropyl 4-(2-thienyl)benzenesulfonate (0.260 g, 0.850 mmol) was 
dissolved in DCM (3.00 mL). A solution of bromine (0.050 mL, 1.02 mmol) in 
dichloromethane (1.40 mL) was added dropwise over 30 min. The reaction was 
stirred at ambient temperature for 2 hrs. A 1.00 M aqueous solution of sodium 
carbonate (5.00 mL) was added and the mixture was stirred. The layers were 
separated and the aqueous phase was extracted with additional dichloromethane 
(15.0 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated to give 0.320 g (96 yield%) of dimethylpropyl 4-(5-bromo-2-
thienyl)benzenesulfonate 4-5 .10 1H NMR (400 MHz, CDCl3)   δ 0.860 - 0.950 
(m, 9 H) 3.71 (s, 2 H) 7.09 (d, J=3.90 Hz, 1 H) 7.20 (d, J=3.90 Hz, 1 H) 7.62 - 
7.70 (m, J=8.59 Hz, 2 H) 7.90 (d, J=8.20 Hz, 2 H);  13C NMR (101 MHz, CDCl3)   
δ 25.3 - 27.3, 31.9, 80.0, 114.4, 125.6, 125.9, 128.9, 131.5, 134.9, 138.8, 143.4  
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3-(5-bromo-2-thienyl)pyridine [4-6] 
S N
C12H25
Br
I
 
Compound 4 - 6 
 
 
The 4-2 3-(5-bromo-2-thienyl)pyridine (0.220 g, 0.920 mmol) was placed into a 
roundbottom flask with 1-Iodododecane (0.410 g, 1.40 mmol) neat.  The reaction 
was allowed to stir overnight at room temperature.  The reaction solution was 
dissolved in hexane and the solvent was decanted.  This was repeated twice to 
yield 3-(5-bromo-2-thienyl)-1-dodedecanylpyridinium iodide, a brown oil of 0.416 
g (85.0% yield) as the title compound 4-6. 1H NMR (400 MHz, CDCl3)   δ 0.87 (t, 
J=6.64 Hz, 3 H) 1.17 - 1.50 (m, 20 H) 2.01 - 2.12 (m, J=7.03 Hz, 2 H) 5.06 (t, 
J=7.42 Hz, 2 H) 7.12 (d, J=3.90 Hz, 1 H) 7.98 (d, J=3.90 Hz, 1 H) 8.16 (dd, 
J=8.20, 6.25 Hz, 1 H) 8.52 (d, J=8.20 Hz, 1 H) 9.15 (d, J=5.86 Hz, 1 H) 9.85 (s, 1 
H);  13C NMR (101 MHz, CDCl3)   δ 13.9, 22.4, 25.7, 28.9, 29.1, 29.2, 29.3 - 
29.5 (m, J=4.42 Hz, 3) 31.6, 31.8, 61.8, 116.9, 128.5, 130.0, 132.1, 134.1, 135.8, 
140.0, 140.3, 141.9  
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3-(5-bromo-2-thienyl)-1-dodedecanylpyridinium-4-(5-bromo-2-
thienyl)benzenesulfonate [4-7] 
S
Br
N
C12H26 S
Br
S
O
O
O
 
Compound 4 - 7 
 
4-6 3-(5-bromo-2-thienyl)-1-dodedecanylpyridinium iodide (0.086 g, 0.160 mmol) 
was dissolved in 1.00 mL of DMSO and a solution of 4-(5-bromo-2-
thienyl)benzenesulfonate (0.057g, 0.160 mmol) in 1.00 mL of DMSO was added.  
After addition of water (1.00 mL) the desired salt was obtained as an off white 
solid (0.090 g, 74% yield) to the title compound 4-7.    1H NMR (400 MHz, 
DMSO-d6)   δ 0.85 (t, J=6.83 Hz, 2 H) 1.19 - 1.33 (m, 20 H) 1.95 (q, J=6.64 Hz, 
2 H) 4.59 (t, J=7.61 Hz, 2 H) 7.25 (d, J=3.90 Hz, 1 H) 7.38 (d, J=3.90 Hz, 1 H) 
7.47 (d, J=3.90 Hz, 1 H) 7.53 - 7.59 (m, J=8.59 Hz, 2 H) 7.59 - 7.64 (m, J=8.59 
Hz, 2 H) 7.76 (d, J=3.90 Hz, 1 H) 8.15 (dd, J=8.20, 6.25 Hz, 1 H) 8.76 (d, J=8.98 
Hz, 1 H) 8.98 (d, J=6.25 Hz, 1 H) 9.43 (s, 1 H); 13C NMR (101 MHz, DMSO-d6)   
δ 13.8 - 14.2, 21.6 - 22.3, 25.2 - 25.6, 28.3 - 28.5, 28.7 - 28.8, 28.7 - 28.8, 28.9 – 
29.0, 28.9 - 29.1, 30.4 - 30.9, 31.3, 61.1,110.8, 115.5, 124.8, 126.3, 128.3, 129.2, 
129.3, 131.8 ,132.4, 132.5, 132.7, 133.0, 137.1, 140.5, 141.1, 143.9, 144.6, 
148.0 
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C-dodecyltetrabromorescorcin[4]arene [4-8] 12 
 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
Br
Br Br
Br
 
Compound 4 - 8 
 
Bromochloromethane (493 mmol 33 mL) was added to a slurry of C-
dodecyltetrabromocalix[4]resorinarene (50.0 g, 35.0 mmol), potassium carbonate 
(68.0 g, 493 mmol) and DMF 1350 mL and the mixture was stirred at 65° C for 
three days under nitrogen. Every 24 hours, more bromochloromethane (4.70 mL, 
70.0 mmol) was added. The DMF was removed in vacuo to give a dark brown 
gum.  Diethyl Ether was added to the residue followed by 2.00 M HCl with 
stirring.  The aqueous phase were separated and extracted with more diethyl 
ether. The combined organic layers were washed with water, saturated brine, 
dried over magnesium sulfate and filtered. Evaporation of the solvent yielded a 
clear brown gum that was purified with column chromatography, 9:1 hexane:ethyl 
acetate, to yield pure product as a light brown oil to give the title compound 4-8.12 
1H NMR (400 MHz, CDCl3)   δ 0.890 (t, J=6.64 Hz, 12 H) 2.20 (d, J=7.81 Hz, 8 
H) 4.33 (d, J=7.42 Hz, 4 H) 4.86 (t, J=8.00 Hz, 4 H) 5.98 (d, J=7.42 Hz, 4 H) 7.07 
(s, 4 H); 13C NMR (101 MHz, CDCl3)   δ 14.3, 22.9, 27.9, 29.6, 29.9, 30.3, 32.1, 
38.1, 93.2, 98.9, 120.8, 138.9, 155.1  LRMS calculated for C76H108Br4O8 1464.48 
found  (M+)1468.6 
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A,C Bis-boronic acid- C,D-bis-bromo resocin[4]arene [3-12] 6 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H HH
H
Br
B(OH)2 B(OH)2 Br
 
Compound 4 - 9 
 
Dry THF (40.0 mL) was added to a sealed tube with a stir-bar containing 
tetrabromo cavitand 4-8 (4.10 g, 2.80 mmol).  The resulting solution was 
evaporated to dryness and heated to 80°C for one hour.  The vacuum was 
replaced with nitrogen and the procedure was repeated two more times.  Dry 
THF (200 mL) was added to the dried tetrabromo cavitand.  The reaction vessel 
was chilled to   -78°C with a dry ice temperature bath and n-butyllithium (0.380 g, 
3.70 mL of 1.60 M in hexanes, 2.10 eqiv.) was added. After 20 minutes of 
stirring, triisopropyl borate (4.20 g, 22.0 mmol, 5.20 mL) was added to the 
reaction vessel at -78°C.  After stirring for 30 minutes, 2.50 M of HCl was added 
to the reaction vessel and allowed a stir for an additional 30 minutes.  The 
reaction solution was transferred to a separtory funnel.  Methylene chloride and 
brine were added to the flask.  The organic and aqueous layers were separated 
and the aqueous layer was washed a second time with methylene chloride.  The 
organic layers were combined, dried with magnesium sulfate, filtered and 
concentrated.  The resulting oil was purified by column chromatography with the 
product eluting with 50:50 hexane:ethyl acetate (1.82 g, 46% yield) to give the 
title compound 4-9.6 1H NMR (400 MHz, CDCl3)   δ 0.89 (none, J=6.64 Hz, 8 H) 
136 
1.36 (q, 99 H) 2.23 (q, J=7.81 Hz, 8 H) 4.45 (d, J=7.42 Hz, 4 H) 4.81 (s, 3 H) 5.60 
(s, 4 H) 5.90 (d, J=7.42 Hz, 4 H) 7.06 (s, 2 H) 7.20 (s, 2 H);  13C NMR (101 MHz, 
CDCl3)   δ 14.0 - 14.3, 22.5 - 22.9, 27.5 - 28.0, 29.2 - 29.6, 29.5 - 29.9, 29.9 - 
30.3, 31.8 - 32.1, 36.6 - 37.4, 98.9 - 99.5, 113.3, 118.8, 123.4, 138.1, 139.2, 
152.1, 158.6  
 
 
A,C-bis 3-(5-bromo-2-thienyl)pyridine resocin[4]arene  [4-
10] 
 
Br
OO O
O
O
O O O
C11H23
C11H23C11H23
C11H23
H
H
H
H
Br
S S
N N
 
Compound 4 - 10 
 
A,C bis boronic acid cavitand 4-9(1.00 g, 0.715 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.083 g, 0.0710 mmol), 3-(5-bromo-2-
thienyl)pyridine 4-2 (0.515 g, 2.14 mmol), 2.00 M sodium bicarbonate (1.50 ml) 
and toluene (4.00 ml) was placed in a sealed tube. The reaction vessel was de-
gassed by freeze-pump-thaw three times and heated for 8 hours at 70°C.  The 
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reaction vessel was allowed to reach room temperature and the contents were 
washed with a saturated sodium bicarbonate solution. Methylene chloride was 
added and the organic layer was washed with a brine solution. The organic layer 
was dried with magnesium sulfate, filtered and concentrated to yield a light-
brown residue. The product was isolated by column chromatography to yield the 
desired A,C-bis 3-(5-bromo-2-thienyl)pyridine resocin[4]arene  to give 0.850 g 
(73% yield) as a light brown residue of the title compound 4-10. 1H NMR (400 
MHz, CDCl3)   δ 1.23 - 1.51 (m, 80 H) 2.27 (d, J=3.90 Hz, 8 H) 4.42 (d, J=7.42 
Hz, 4 H) 4.90 (t, J=8.00 Hz, 3 H) 5.85 (d, J=7.42 Hz, 4 H) 7.15 (s, 2 H) 7.19 (s, 1 
H) 7.20 (d, J=3.90 Hz, 1 H) 7.33 (dd, J=5.08 Hz, 2 H) 7.36 (d, J=3.51 Hz, 2 H) 
7.87 (dd, J=6.05, 2.15 Hz, 2 H) 8.54 (d, J=3.51 Hz, 2 H) 8.89 (d, J=1.95 Hz, 2 H); 
13C NMR (101 MHz, CDCl3)   δ 14.1,22.7,27.8,29.4,29.7, 30.2, 31.9, 37.4, 99.5, 
113.2, 119.0, 120.5, 122.1, 123.7, 124.2, 130.0, 130.1, 132.8, 133.8, 138.6, 
139.2, 140.9, 146.8, 148.6, 152.2, 152.5 LRMS calc. for C94H120Br2N2O8S2 
1626.7 found (M+) 1629.9 
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A,C-bis 3-(5-bromo-2-thienyl)methyl pyridinium iodide 
resorcin[4]arene [4-11] 
 
 
Br
OO O
OO
O O O
R
RR
R
H
HH
H
H
S S
N N
I I
 
Compound 4 - 11 
 
The A,C-bis 3-(5-bromo-2-thienyl)pyridine resorcin[4]arene 4-10 (0.23 g 14.0 
mmol), methyl iodide (0.847 mmol 0.050 mL) and THF (1.00 mL) were added to 
a sealed reaction container.  The reaction was allowed to stir overnight at room 
temperature.  The solvent was removed via vacuum and the remaining residue 
was dissolved in methyl chloride.  The methylene chloride was washed with 
brine.  The organic layer was dried with magnesium sulfate, filtered and 
concentrated to yield the desired A,C-bis 3-(5-bromo-2-thienyl)methyl pyridinium 
iodide cavitand as a brown residue to give 0.19 g (85.0% yield) of the title 
compound 4-11. 1H NMR (400 MHz, CDCl3)   δ 1.19 - 1.51 (m, 84 H) 2.25 (s, 8 
H) 4.42 (d, J=7.03 Hz, 4 H) 4.72 (s, 6 H) 4.85 (t, J=8.00 Hz, 4 H) 5.83 (d, J=7.03 
Hz, 2 H) 7.11 (s, 2 H) 7.19 (s, 2 H) 7.29 (d, J=3.90 Hz, 1 H) 7.95 (d, J=3.90 Hz, 1 
H) 8.05 (dd, J=6.64 Hz, 1 H) 8.56 (d, J=8.20 Hz, 1 H) 8.99 (d, J=5.08 Hz, 2 H); 
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13C NMR (101 MHz, CDCl3) d δ 14.1,22.6,27.9,29.4,29.7 29.9, 30.2, 31.5, 31.9, 
37.4, 49.5, 99.5, 113.4, 121.2, 128.3, 128.9, 130.4, 130.6, 131.0, 133.2, 133.3, 
134.7, 135.1, 137.8, 138.5, 138.9, 140.2, 141.4, 142.7, 152.1, 152.3 LRMS calc 
for C96H126Br2N2O8S2 1910.5 found 1786.8  
 
 
A,C-bis-3-Dimethylpropyl 4-(5-bromo-2-thienyl)benzenesulfonate 
resorcin[4]arene [4-12] 
O O
OO
O O O
C11H23
C11H23
C11H23
C11H23
H
HH
H
Br Br
S
S
S
O
OO
S
O
OO
 
Compound 4 - 12 
 
The A,C bis boronic acid cavitand 4-9 (0.320 g, 0.230 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.030 g, 0.023 mmol), 2,2-
dimethylpropyl 4-(5-bromo-2-thienyl)benzenesulfonate 4-5 (0.270 grams 0.690 
mmol), 2.00 M sodium bicarbonate (1.00 ml) and toluene (3.00 ml) was placed in 
a sealed tube. The reaction vessel was then de-gassed by freeze-pump-thaw 
three times and heated for eight hours at 80°C.  The reaction vessel was allowed 
to reach room temperature and the contents were washed with a saturated 
sodium bicarbonate solution. The organic layer was washed with a brine solution, 
dried with magnesium sulfate, filtered and concentrated to yield a light-brown 
residue. The product was isolated by column chromatography to yield the A,C 
dimethylpropylbissulfonate-cavitand as an off-white residue to give (0.340 g, 77% 
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yield) of the title compound 4-12.   1H NMR (400 MHz, CDCl3)   δ 0.790 - 1.01 
(m, 34 H) 1.15 - 1.65 (m, 83 H) 2.28 (s, 8 H) 3.71 (s, 4 H) 4.41 (d, J=7.42 Hz, 4 
H) 4.90 (t, J=8.00 Hz, 4 H) 5.86 (d, J=7.03 Hz, 4 H) 7.17 (s, 1 H) 7.21 (s, 2 H) 
7.23 (d, J=3.90 Hz, 2 H) 7.44 (d, J=3.90 Hz, 2 H) 7.75 (d, J=8.59 Hz, 3 H) 7.91 
(d, J=8.59 Hz, 4 H); 13C NMR (101 MHz, CDCl3)   δ 14.1, 22.7, 26.0, 27.8, 29.4, 
29.7, 30.1, 31.6, 31.9, 37.4, 79.7, 99.4, 113.1, 119.1, 120.7, 121.8, 125.2, 125.8, 
128.6, 130.3,134.3,134.9,138.6,139.0,139.2,142.2,152.1,152.4  
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A,C Bis sulfonate thiophene tetramethyl ammonium 
resocin[4]arene [4-13] 
O O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
S S
S
S
O
O
O
O
O
O
Br
Br
N
N
 
Compound 4 - 13 
 
The A,C dimethylpropylbissulfonate-cavitand 4-12 (0.073 g, 0.038 mmol), tetra-
methyl ammonium chloride (0.041 g, 0.380 mmol) and DMF (0.500 mL) was 
placed in a sealed tube. The reaction vessel was heated at 150°C for 24 hours.  
The reaction solution was allowed to cool to room temperature and the DMF was 
removed in vacuo. The remaining residue was dissolved in methylene chloride 
and washed with brine solution. The organic layer was dried with magnesium 
sulfate, filtered and concentrated to yield a light brown residue. The product was 
isolated using C18 reverse phase column chromatography with 100% THF to 
yield the product as an off white solid to give (0.213 g,  99% yield) of the title 
compound 4-13.11 1H NMR (400 MHz, CDCl3)   δ 0.880 (t, J=6.64 Hz, 12 H) 2.27 
(s, 8 H) 3.31 (s, 24 H) 4.36 (d, 4 H) 4.36 (s, J=5.47 Hz, 2 H) 4.86 (t, J=7.22 Hz, 4 
H) 4.86 (t, J=7.22 Hz, 2 H) 5.77 (d, J=5.47 Hz, 4 H) 5.77 (d, J=5.47 Hz, 4 H) 7.11 
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(s, 2 H) 7.11 (s, 2 H) 7.16 (s, 2 H) 7.16 (s, 2 H) 7.18 (d, J=3.51 Hz, 2 H) 7.18 (d, 
J=3.51 Hz, 2 H) 7.32 (d, J=3.51 Hz, 1 H) 7.32 (d, J=3.51 Hz, 2 H) 7.57 (d, J=8.20 
Hz, 4 H) 7.57 (d, J=8.20 Hz, 4 H) 7.83 (d, J=7.81 Hz, 4 H) 7.83 (d, J=7.81 Hz, 4 
H) 7.83 (d, J=7.81 Hz, 4 H); 13C NMR (101 MHz, CDCl3)   δ 14.1, 22.7, 27.9, 
29.4, 29.7, 29.8, 30.2, 30.3, 31.9, 37.4, 55.4, 99.4, 113.3, 118.9, 120.4, 122.4, 
124.0, 125.4, 126.5, 130.5, 132.95, 135.1, 138.5, 139.1, 143.5, 145.5, 152.2, 
152.5  
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A,C Bis sulfonate-A,C bis pyridinium capsule 4-14 
Br
OO O
OO
O O O
C11H23
C11H23C11H23 C11H23
H
HH
H
H
S S
S S
O
O
O
O
O
O
Br
O OO
O
O
OO
O
C11H23C11H23 C11H23
C11H23
H
H HH
H
SS
NN
 
Compound 4 - 14 
 
The A,C-bis methyl pyridinium iodide cavitand 4-11(0.021 g, 0.0109 mmol) and 
the A,C bissulfonate-cavitand 4-13(0.0108 g, 0.0108 mmol) was dissolved 
separately in 1.00 mL of DMSO.  The two solutions were mixed together at room 
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temperature and immediately a white precipitation occurred.  The precipitation 
was isolated via filtration to yield an off white solid of 0.030 g to give (79% yield) 
as the title compound 4-14. 1H NMR (400 MHz, CDCl3)   δ 0.670 - 1.00 (m, 24 
H) 1.18 - 1.50 (m, 164 H) 2.24 (s, 16 H) 4.26 - 4.45 (m, 8 H) 4.61 (s, 6 H) 4.75 - 
4.94 (m, 8 H) 5.68 - 5.86 (m, 8 H) 7.06 - 7.25 (m, 12 H) 7.29 - 7.36 (m, 2 H) 7.53 
(s, 4 H) 7.82 (s, 6 H) 7.88 - 8.01 (m, 2 H) 8.40 (s, 2 H) 8.94 (s, 2 H) 9.48 (s, 2 H); 
13C NMR (101 MHz, DMSO-d6)   δ 12.5, 20.9, 26.3, 27.6, 27.9, 28.0, 30.1, 36.1, 
46.8, 97.6, 110.8, 110.9, 119.2, 119.4, 119.5, 120.3, 120.5, 121.3, 121.8, 123.2, 
125.0, 126.4, 126.5, 128.6, 129.3, 131.2, 132.5, 132.8, 133.8, 135.8, 137.0, 
137.1, 137.8, 138.6, 140.4, 141.5, 142.2, 145.3, 150.1, 150.2, 150.3 
 
 
 
 
 
Potassium 4-(5-bromo-2-thienyl)benzenesulfonate [3-7] 
 
SO O
O
S
Br
K
 
compound 3- 25 
phenyl 4-(5-bromo-2-thienyl)benzenesulfonate  .52 grams (1.31 mmol) and 10 
mL of CH2Cl2 and 10 mL of methanol was placed into a small round bottom flask.  
.73 grams (13 mmol) of KOH was dissolved in 5 mL of CH3OH. The reaction was 
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cooled to 0oC and slowly the KOH solution was added to reaction. A precipitate 
was filtered to produce .435 grams (1.22 mmol) 93 % yield of the title compound 
3-7. 1H NMR (200 MHz, DMSO-d6) d ppm 7.264 (d, J=3.66 Hz, 1 H) 7.393 (d, 
J=3.66 Hz, 1 H) 7.598 (d, J=8.42 Hz, 4 H) 13C NMR (101 MHz, DMSO-d6) d ppm 
110.817, 124.521, 124.675, 126.403, 31.786, 132.687, 144.589, 147.94 
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C-pentylmethylcalix[4]resorcinarene[2-1] 1H 
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C-pentylmethylcalix[4]resorcinarene[2-1] 13C 
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C-pentyltetramethylresorcin[4]arene [2-2] 1H 
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Chemical Shift (ppm)
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C-pentyltetramethylresorcin[4]arene [2-2] 13C 
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Chemical Shift (ppm)
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C-Pentyltetrabenzylbromideresorcin[4]arene [2-3] 1H 
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Chemical Shift (ppm)
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C-Pentyltetrabenzylbromideresorcin[4]arene [2-3] 13C 
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C-Pentyltetrabenzylazide resorcin[4]arene [2-4] 1H 
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C-Pentyltetrabenzylazide resorcin[4]arene [2-4] 13C 
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C-Pentyltetraphenyl-1,2,3-triazoleresorcin[4]arene [2-5] 1H 
 
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
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C-Pentyltetraphenyl-1,2,3-triazoleresorcin[4]arene [2-5] 13C 
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Chemical Shift (ppm)
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Phenyl 4-bromobenzenesulfonate[2-6] 1H 
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Chemical Shift (ppm)
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Phenyl 4-ethynltrimethylsilanebromobenzenesulfonate[2-7] 1H 
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Phenyl 4-ethynylbenzenesulfoate [2-8] 1H 
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Silyl-3-(3,3-dimethylbut-1-yn-1-yl)pyridine[2-9] 1H 
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Chemical Shift (ppm)
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Silyl-3-(3,3-dimethylbut-1-yn-1-yl)pyridine[2-9] 13C 
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Chemical Shift (ppm)
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3-ethynylpyridine [2-10] 1H  
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 
Chemical Shift (ppm) 
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3-ethynylpyridine [2-10] 13C 
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A,C-Bis-1,2,3-triazole 3-pyridine resorcin[4]arene [2-11] 1H 
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A,C-Bis-1,2,3-triazole 3-pyridine resorcin[4]arene [2-11] 13C 
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A,C-bis-1,2,3-triazole 3-pyridine-B,D-1,2,3-triazole phenyl benzene sulfonate [2-12] 1H 
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A,C-bis-1,2,3-triazole 3-pyridine-B,D-1,2,3-triazole phenyl benzene sulfonate [2-12] 13C 
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A,B-Bis-1,2,3,triazole 3-pyridine resorcin[4]arene [2-13] 1H 
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Chemical Shift (ppm)
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A,B-Bis-1,2,3,triazole 3-pyridine resorcin[4]arene [2-13] 13C 
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A,B-Bis-1,2,3 triazole 3-pyridine-C,D-1,2,3-triazole phenyl benzne sulfonate [2-14] 1H 
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Chemical Shift (ppm)
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2,2-dimethylpropyl4-bromobenzenesulfonate [3-3]1H 
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2, 2 dimethylpropyl 4-(2-thienyl)benzenesulfonate[3-4] 1H 
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2, 2 dimethylpropyl 4-(2-thienyl)benzenesulfonate[3-4] 13C 
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  Dimethylpropyl 4-(5-bromo-2thienyl)benzenesulfonate [3-5] 1H 
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3-(5-bromo-2-thienyl)pyridine [3-6] 1H 
 
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
3.3818.342.182.011.010.971.020.961.00
9
.
8
5
9
.
1
6
9
.
1
4
8
.
5
3
8
.
5
1
8
.
1
6
7
.
9
9
7
.
9
8
7
.
1
2
7
.
1
1
5
.
0
8
5
.
0
7
5
.
0
5
2
.
0
9
2
.
0
7
1
.
4
4
1
.
4
2
1
.
4
1
1
.
3
3
1
.
2
6
1
.
2
2
1
.
1
7
0
.
8
8
0
.
8
7
0
.
8
5
S
Br
N
+
C
H
3
I
-
181 
                   
 
 
S
Br
N
+
C
H
3
I
-
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
1
4
1
.
8
8
1
4
0
.
3
0
1
4
0
.
0
1
1
3
4
.
0
5
1
3
2
.
1
4
1
3
0
.
0
0
1
2
8
.
5
5
1
1
6
.
9
0
7
7
.
3
2
7
7
.
0
0
7
6
.
6
9
6
1
.
7
9
3
1
.
8
4
3
1
.
6
4
2
9
.
3
5
2
9
.
0
8
2
8
.
9
0
2
2
.
4
3
1
3
.
9
0
3-(5-bromo-2-thienyl)pyridine) [3-6] 13C 
182 
Potassium 4-(5-bromo-2thienyl)benzensulfonate) [3-7] 1H 
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Potassium 4-(5-bromo-2thienyl)benzensulfonate) [3-7] 13C 
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  3-(5-bromo-2-thienyl)-1-dodecanylpyridinium -4-(5-bromo-2-thienyl)benzenesulfonate [3-8] 1H 
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3-(5-bromo-2-thienyl)-1-dodecanylpyridinium -4-(5-bromo-2-thienyl)benzenesulfonate [3-8] 13C 
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C-dodecyltetrabromorescorcin[4]arene [3-11] 1H 
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C-dodecyltetrabromorescorcin[4]arene [3-11] 13C 
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    A,C Bis-boronic acid-C,D bis-bromo resorcin[4]arene [3-12] 13C 
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A,C Bis-thiophene pyridine-C,D-bis-bromo resorcin[4]arene [3-13] 1H 
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A,C Bis-thiophene pyridine-C,D-bis-bromo resorcin[4]arene [3-13] 13C 
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  A,C Bis-thiophene pyridine-C,D-bis-iodoresorcin[4]arene [3-14] 1H 
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    A,C Bis-thiophene pyridine-C,D-bis-iodo resorcin[4]arene [3-14] 13C 
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A,C Bis-thiophene pyridine-C,D Bis thiophene dimethylpropylbenzenesulfonate[3-15] 1H 
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A,C Bis-thiophene pyridine-C,D Bis thiophene dimethylpropylbenzenesulfonate[3-15] 13C 
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A,C Bis-thiophene pyridinium triflate-C,D bis-thiophene dimethylpropylbenzesulfonate resorcin[4]arene [3-16] 1H 
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 A,C Bis-thiophene pyridinium triflate-C,D bis-thiophene dimethylpropylbenzesulfonate resorcin[4]arene [3-16] 13C 
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Tetraiodo resorcin[4]arene [3-18] 1H 
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     Tetraiodo resorcin[4]arene [3-18] 13C        
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Mono-thiophene-dimethylpropylbenzenesulfonate-mono-iodo-bishydrogne resorcin[4]arene [3-20] 1H 
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Mono-thiophene-dimethylpropylbenzenesulfonate-mono-iodo-bishydrogne resorcin[4]arene [3-20] 13C 
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 A,B-Mono-thiophene-dimethylpropylbenzenesulfonate-mono-thiophene-pyridine bis hydrogen resorcin[4]arene [3-21] 1H 
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A,B-Mono-thiophene-dimethylpropylbenzenesulfonate-mono-thiophene-pyridine bis hydrogen resorcin[4]arene [3-21] 13C 
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A,B-Mono-thiophene-dimethylpropylbenzenesulfonate-mono-thiophene-pyridinium-triflate-bis hydrogen resorcin[4]arene [3-22] 1H 
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A,B-Mono-thiophene-dimethylpropylbenzenesulfonate-mono-thiophene-pyridinium-triflate-bis hydrogen resorcin[4]arene [3-22] 13C 
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  2-butyl-5-(2-thienyl)pyridine[3-23] 1H 
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2-butyl-5-(2-thienyl)pyridine[3-23] 13C 
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5-(5-bromo2-thienyl)-2-butyl-5-(2-thienyl)pyridine[3-23] 1H 
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5-(5-bromo-2-thienyl)-2-butyl-5-(2-thienyl)pyridine[3-23] 13C 
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A,C Bis 3-( 2-thienyl)pyridine resocin[4]arene  [4-10] 1H 
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A,C Bis 3-( 2-thienyl)pyridine resocin[4]arene  [4-10] 13C 
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A, C- Bis 3-(2-thienyl)methyl pyridinium iodide resorcin[4]arene [4-11] 1H 
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A, C- Bis 3-(2-thienyl)methyl pyridinium iodide resorcin[4]arene [4-11] 13C 
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A, C-bis-3-dimethylpropyl 4-(2-thienyl)benzenesulfonate resorcin[4]arene [4-12] 1H 
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Chemical Shift (ppm)
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A, C-bis-3-dimethylpropyl 4-(2-thienyl)benzenesulfonate resorcin[4]arene [4-12] 13C 
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A,C Bis sulfonate thiophene tetramethyl ammonium resorcin[4]arene [4-13] 1H 
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A,C Bis sulfonate thiophene tetramethyl ammonium resorcin[4]arene [4-13] 13C 
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Sulfonate-pyridinium Dimeric Capsule [4-14] 1H 
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Chemical Shift (ppm)
23.7015.698.118.298.0012.523.992.521.752.451.98
9
.
4
8
8
.
9
4
8
.
4
0
7
.
8
2
7
.
5
3
7
.
2
6
5
.
7
7
4
.
8
5
4
.
6
1
4
.
3
6
3
.
2
8
2
.
6
1
2
.
5
6
2
.
2
4
1
.
9
0
1
.
2
7
0
.
8
8
0
.
0
0
OO
O O
OOO
C11H23C11H23 C11H23
C11H23
HH
H
H
S
S
S
S
O
O
O
O
O
O
Br
Br
O
O
O
O
O O
O
C11H23 C11H23
C11H23 C11H23
H
HH H
S
S
N
N
Br Br
221 
       Sulfonate-pyridinium Dimeric Capsule [4-14] 13C 
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Bis-sulfonate-para-dimethylpyridinium 1H [4-15] 
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Chemical Shift (ppm)
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Bis-sulfonate-para-dimethylpyridinium  [4-15] 13C 
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C-dodecy calix[4]resorcinarene [3-9] LRMS 
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C-dodecytetrabromocalix[4]resorinarene [3-10] LRMS       
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   C-dodecyltetrabromo resorcin[4]arene [3-11] LRMS        
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A,C Bis-boronic acid-C,D-bis-bromo resorcin[4]arene [3-12] LRMS 
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A,C Bis-thiophene-C,D-bis-bromo resorcin[4]arene [3-13] LRMS 
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A,C Bis-thiophene-C,D-bis-iodo resorcin[4]arene [3-14] LRMS 
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A,C bis-thiophene pyridine-C,D bis-thiophene dimethylpropylbenzenesulfonate [3-15] LRMS 
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A,C Bis-thiophene pyridinium triflate-C,D bis-thiophene dimethylpropylbenzenesulfonate resorcin[4]arene [3-16] LRMS 
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A,C bis-thiophene pyridinium C,D bis-thiophene-benzenesulfonate resorcin[4]arene [3-17] LRMS 
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A,B-bis-iodo-C,D-bis-hydrogen resorcin[4]arene [3-19] LRMS 
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A,B-3(2-thienyl)pyridinium-4(2-thienyl)benzenesulfonate  LRMS 
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A,C Bis-3(2-thienyl)pyridine resorcin[4]arene [4-10] 
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A,C-bis 3(2-thienyl) methyl pyridinium iodide resorcin[4]arene [4-11] LRMS 
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3-(5-bromo-2-thienyl)pyridinium [4-6] LRMS 
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4-(5-bromo-2-thienyl)sulfonate [4-6] LRMS 
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